



**April 2017**

Drug Information Update

## TABLE OF CONTENTS

---

NEWLY AVAILABLE GENERICS .....	2
NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS .....	3
NEW INDICATIONS (EXISTING DRUGS) .....	6
FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS .....	8
STUDIES and RECENT TOPICS.....	10
RECALLS.....	16
CURRENT DRUG SHORTAGES.....	27

## NEWLY AVAILABLE GENERICS

GENERIC DRUG NAME	STRENGTH & DOSAGE FORM	GENERIC MANUFACTURER	BRAND NAME
DEXAMETHASONE	1.5 MG (41 TABS)	ORGANON PHARM	ZONACORT
DEXAMETHASONE	1.5 MG (27 TABS)	ORGANON PHARM	ZONACORT
BUSULFAN	60 MG/10 ML VIAL	AMER REGENT	BUSULFEX
NOREPINEPHRINE BIT/0.9% NACL	16 MG/250ML (64 MCG/ML)	PHARMEDIUM	NOREPINEPHRINE BIT/0.9% NACL
ZILEUTON	600 MG TBMP 12 HR	CHIESI USA INC	ZYFLO CR
SODIUM FLUORIDE	1.10% PASTE	KIRKMAN LABS	FLUORIDEX
TAZAROTENE	0.10% CREAM	ALLERGAN INC	TAZORAC
MORPHINE SULFATE IN 0.9 % NACL	30 mg/30 mL (1 mg/mL) PCA SYRINGE	PURDUE FREDERIC	MORPHINE SULFATE-0.9% NACL
UREA	45% LOTION	CROWN LABORATORIES	URAMAXIN
VANCOMYCIN/0.9 % SOD CHLORIDE	1.75G/500 ML	HOSPIRA	VANCOMYCIN HCL-0.9% NACL
VANCOMYCIN/0.9 % SOD CHLORIDE	2G/500 ML	HOSPIRA	VANCOMYCIN HCL-0.9% NACL
VANCOMYCIN/0.9 % SOD CHLORIDE	2G/250 ML	HOSPIRA	VANCOMYCIN HCL-0.9% NACL

## NEW DRUG ENTITIES/COMBINATIONS/STRENGTHS

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
SILIQ 210 MG/1.5 ML SUBCUTANEOUS SYRINGE	SILIQ	BRODALUMAB	210 MG/1.5 ML	NEW ENTITY
IXINITY 250 UNIT INTRAVENOUS SOLUTION	IXINITY	FACTOR IX HUMAN RECOMB,THR 148	250 UNIT	NEW STRENGTH
IXINITY 2000 UNIT INTRAVENOUS SOLUTION	IXINITY	FACTOR IX HUMAN RECOMB,THR 148	2,000 UNIT	NEW STRENGTH
IXINITY 3000 UNIT INTRAVENOUS SOLUTION	IXINITY	FACTOR IX HUMAN RECOMB,THR 148	3,000 UNIT	NEW STRENGTH
PAINGO KFT 2.5 %-2.5 %-30 %-10 % TOPICAL CREAM	PAINGO KFT	LIDOCAINE/PRILO/M.SALICY/ MENTH	2.5 %-2.5 %-30 %-10 % CREAM	NEW COMBINATION
LARTRUVO 10 MG/ML INTRAVENOUS SOLUTION	LARTRUVO	OLARATUMAB	190 mg/19 mL (10 mg/mL)	NEW STRENGTH
VANCOMYCIN 100 GRAM SOLUTION FOR INJECTION	VANCOMYCIN	VANCOMYCIN HCL	100 GRAM	NEW DOSAGE FORM
SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE	SYNJARDY XR	EMPAGLIFLOZIN/METFORMIN HCL	5 mg-1,000 mg	NEW DOSAGE FORM
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE	SYNJARDY XR	EMPAGLIFLOZIN/METFORMIN HCL	10 mg-1,000 mg	NEW STRENGTH AND DOSAGE FORM
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE	SYNJARDY XR	EMPAGLIFLOZIN/METFORMIN HCL	12.5 mg-1,000 mg	NEW DOSAGE FORM

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE	SYNJARDY XR	EMPAGLIFLOZIN/METFORMIN HCL	25 mg-1,000 mg	NEW STRENGTH AND DOSAGE FORM
OCREVUS 30 MG/ML INTRAVENOUS SOLUTION	OCREVUS	OCRELIZUMAB	300 mg/10 mL	NEW ENTITY
MORPHINE 1,000 MG/100 ML (10 MG/ML) IN 0.9 % SOD CHL IV PUMP RESERVOIR	MORPHINE SULFATE-0.9% NACL	MORPHINE SULFATE IN 0.9 % NACL	1,000 mg/100 mL (10 mg/mL)	NEW DOSAGE FORM
Epinephrine HCl 200 MCG/10 ML(20 MCG/ML) IN 0.9 % SOD CHLOR IV SYRINGE	EPINEPHRINE HCL-0.9% NACL	EPINEPHRINE HCL IN 0.9 % NACL	200 mcg/10 mL (20 mcg/mL)	NEW STRENGTH
EPHEDRINE SULFATE 50 MG/ML INTRAVENOUS SOLUTION	EPHEDRINE SULFATE	EPHEDRINE SULFATE	50 mg/mL (1 mL)	NEW DOSAGE FORM
DUPIXENT 300 MG/2 ML SUBUTANEOUS SYRINGE	DUPIXENT	DUPILUMAB	300 mg/2 mL	NEW ENTITY
PENNSAID 2 % TOPICAL SOLUTION IN PACKET	PENNSAID	DICLOFENAC SODIUM	2 %	NEW STRENGTH AND DOSAGE FORM
BAVENCIO 20 MG/ML INTRAVENOUS SOLUTION	BAVENCIO	AVELUMAB	200 mg/10 mL (20 mg/mL)	NEW ENTITY
GAMMAPLEX 10 % INTRAVENOUS SOLUTION	GAMMAPLEX	IMMUN GLOB G(IGG)/GLY/IGA 0-50	10 %	NEW ENTITY

DESCRIPTION	BRAND NAME	GENERIC NAME	STRENGTH	NOTES
AUSTEDO 6 MG TABLET	AUSTEDO	DEUTETRABENAZINE	6 MG	NEW ENTITIY
AUSTEDO 9 MG TABLET	AUSTEDO	DEUTETRABENAZINE	9 MG	NEW ENTITIY
AUSTEDO 12 MG TABLET	AUSTEDO	DEUTETRABENAZINE	12 MG	NEW ENTITIY
INDIGOTINDISULFONATE 8 MG/ML (0.8 %) IN WATER INJECTION SOLUTION	INDIGOTINDISULFONATE SOD-WATER	INDIGOTINDISULFONATE IN WATER	8 mg/mL (0.8 %)	NEW ENTITIY
HYDROMORPHONE 250 MG/250 ML (1 MG/ML) IN 0.9 % SOD CHLOR IV PUMP RESV	HYDROMORPHONE HCL-0.9% NACL	HYDROMORPHONE HCL IN 0.9% NACL	250 mg/250 mL (1 mg/mL)	NEW STRENGTH
PHENYLEPHRINE 10 MG/100 ML (100 MCG/ML) IN 0.9 % SODIUM CHLOR IV	PHENYLEPHRINE HCL-0.9% NACL	PHENYLEPHRINE HCL IN 0.9% NACL	10 mg/100 mL (100 mcg/mL)	NEW STRENGTH
HEPARIN (PORCINE) 4,000 UNIT/500 ML (8 UNIT/ML) IN 0.9 % NACL IV SOLN	HEPARIN SODIUM-0.9% NACL	HEPARIN SOD,PORCINE/0.9 % NACL	4,000 unit/500 mL (8 unit/mL)	NEW STRENGTH
GELNIQUE 100 MG/GRAM (10 %) TRANSDERMAL GEL PUMP	GELNIQUE	OXYBUTYNIN CHLORIDE	100 mg/gram per actuation (10 %)	NEW STRENGTH

## NEW INDICATIONS (EXISTING DRUGS)

---

### Juvéderm vollure™ XC

**March 20, 2017**

DUBLIN, March 20, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURE™ XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.1 In the US pivotal clinical trial, a majority (59%) of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months.\* Patient satisfaction in the pivotal study was also high: 82% of patients said they were very satisfied at 6 months and 68% at 18 months.

Source: Allergan plc

<https://www.allergan.com/news/news/thomson-reuters/juv-derm-vollure-xc-approved-by-u-s-fda-for-correc>

### Keytruda®

**March 17, 2017**

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company's anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after three or more prior lines of therapy. Under the FDA's accelerated approval regulations, this indication is approved based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. In refractory or relapsed cHL, KEYTRUDA is approved for use in adult patients at a fixed dose of 200 mg and in pediatric patients at a dose of 2 mg/kg (up to a maximum of 200 mg). KEYTRUDA is administered intravenously every three weeks until disease progression or unacceptable toxicity, or up to 24 months in patients without disease progression.

Source: Merck

<http://investors.merck.com/news/press-release-details/2017/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-Adult-and-Pediatric-Patients-with-Classical-Hodgkin-Lymphoma-cHL-Refractory-to-Treatment-or-Who-Have-Relapsed-After-Three-or-More-Prior-Lines-of-Therapy/default.aspx>

### Ibrance®

**March 31, 2017**

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, IBRANCE® (palbociclib), based on the results from the confirmatory Phase 3 trial PALOMA-2. The FDA action converts the accelerated approval of IBRANCE to regular approval and broadens the range of anti-hormonal therapy that may be administered with IBRANCE. IBRANCE now is indicated in combination with an aromatase inhibitor, expanding on its earlier indication in combination with letrozole, as initial endocrine based therapy in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Source: Pfizer Inc.

[http://www.pfizer.com/news/press-release/press-release-detail/ibrance\\_palbociclib\\_receives\\_fda\\_regular\\_approval\\_and\\_expanded\\_indication\\_for\\_first\\_line\\_hr\\_her2\\_metastatic\\_breast\\_cancer](http://www.pfizer.com/news/press-release/press-release-detail/ibrance_palbociclib_receives_fda_regular_approval_and_expanded_indication_for_first_line_hr_her2_metastatic_breast_cancer)

## Tagrisso®

**March 31, 2017**

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for TAGRISSO® (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after an EGFR tyrosine kinase inhibitor (TKI) therapy. TAGRISSO is the first and only approved medicine in the US indicated for NSCLC patients who have tested positive for the EGFR T790M mutation, and efficacy data suggest it may be a new standard of care for these patients.

Source: AstraZeneca

<https://www.astrazeneca-us.com/media/press-releases/2017/tagrisso-osimertinib-receives-us-fda-full-approval-03312017.html>



## FDA NEWS/BULLETINS/ADVISORIES/SAFETY ALERTS

---

### Viberzi (eluxadolone): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder

[Posted 3/15/2017]

**ISSUE:** FDA is warning that Viberzi (eluxadolone), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, FDA is working with the Viberzi manufacturer, Allergan, to address these safety concerns.

**BACKGROUND:** Viberzi is a prescription medicine used to treat irritable bowel syndrome in adults when the main symptom is diarrhea (IBS-D). IBS-D affects the large intestine and causes cramping, stomach-area or abdomen pain, bloating, gas, and diarrhea. The cause of IBS-D is not known. Viberzi works by decreasing bowel contractions, which leads to less diarrhea. In patients with IBS-D, Viberzi can help ease stomach-area or abdomen pain and improve stool consistency.

**RECOMMENDATION:** Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients. Hospitalizations and deaths due to pancreatitis have been reported with Viberzi use in patients who do not have a gallbladder. Symptoms of pancreatitis have occurred with just one or two doses of Viberzi at the recommended dosage for patients who do not have a gallbladder (75 mg), and who do not consume alcohol.

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm546771.htm>

### Sterile Compounded Products by Isomeric Pharmacy Solutions: Recall - Lack of Sterility Assurance

[Posted 4/6/2017]

**ISSUE:** Isomeric Pharmacy Solutions (“Isomeric”) is voluntarily recalling all lots of sterile products compounded and packaged by Isomeric and that remain within expiry to the hospital/user level because of FDA concerns of a lack of sterility assurance. These concerns were brought to Isomeric’s attention during a recent FDA inspection.

The sterile products were distributed to patients, providers, hospitals, or clinics nationwide between October 4, 2016 and February 7, 2017. See the press release for a link to list of all drugs affected by this recall.

**BACKGROUND:** To date, Isomeric has not received any reports of adverse events related to this recall. This recall does not pertain to any non-sterile compounded medications prepared by Isomeric.

**RECOMMENDATION:** Isomeric is notifying its customers of the recall by mail and telephone or email and is arranging for a return of all recalled products that remain unused. Customers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. Providers who have dispensed any sterile product distributed by Isomeric to a patient(s) for use out of the provider’s office should contact the patient(s) to whom product was dispensed and advise the patient(s) of this recall.

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm551299.htm>

**EpiPen and and EpiPen Jr Auto-Injector: Recall - Failure to Activate Device**  
**[Posted 3/31/2017]**

**ISSUE:** Mylan N.V. announced that Meridian Medical Technologies, a Pfizer company and Mylan's manufacturing partner for EpiPen Auto-Injector, has expanded a voluntary recall of select lots of EpiPen (epinephrine injection, USP) and EpiPen Jr (epinephrine injection, USP) Auto-Injectors to now include additional lots distributed in the U.S. and other markets.

This recall is being conducted as a result of the receipt of two previously disclosed reports outside of the U.S. of failure to activate the device due to a potential defect in a supplier component. The potential defect could make the device difficult to activate in an emergency (failure to activate or increased force needed to activate) and have significant health consequences for a patient experiencing a life-threatening allergic reaction (anaphylaxis). Both reports are related to the single lot that was previously recalled.

The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. The recalled product was manufactured by Meridian Medical Technologies and distributed by Mylan Specialty between December 2015 and July 2016. None of the recalled lots include the authorized generic for EpiPen Auto-Injector, which is also manufactured by Meridian Medical Technologies. See the news release for a list of affected product lot numbers.

**BACKGROUND:** The expanded voluntary recall is being initiated in the U.S. and also will extend to additional markets in Europe, Asia, North and South America.

**RECOMMENDATION:** Patients, customers and distributors are being notified and should refer to [Mylan.com/EpiPenRecall](http://Mylan.com/EpiPenRecall) for updates on product return and replacement instructions. We are asking patients to keep their existing product until their replacement product can be secured.

Patients may receive either EpiPen Auto-Injector or the authorized generic for EpiPen Auto-Injector at the pharmacy as a replacement based on availability. The authorized generic has the exact same drug formulation, has the exact same operating instructions and is therapeutically equivalent to EpiPen Auto Injector, and may be substituted for EpiPen Auto Injector.

It is important that patients continue to carry their current EpiPen Auto-Injector until they receive a replacement device.

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm550165.htm>

## STUDIES and RECENT TOPICS

---

### [Analysis: Reports of Drug Side Effects Increase Fivefold in 12 Years](#)

**March 17, 2017**

More than 1 million reports of drug side effects were filed with the U.S. Food and Drug Administration in 2015, a fivefold increase since 2004, according to an analysis by the Milwaukee Journal Sentinel and MedPage Today. Numbers aren't final for 2016, but are expected to match that all-time high.

Source: [jsonline.com](#)

### [Sanofi's Xyzal Allergy 24HR Hits Store Shelves](#)

**March 21, 2017**

Sanofi Consumer Healthcare has rolled out Xyzal Allergy 24HR, an over-the-counter oral antihistamine, to retail stores nationwide. Sanofi said Tuesday that Xyzal, which had been available by prescription only for nearly a decade, is now available OTC in two formulations: 5-mg tablets for ages 6 years and older, and a 0.5 mg/ml oral solution for ages 2 years and older. The company announced Food and Drug Administration approval for the OTC product in February.

Source: [chaindrugreview.com](#)

### ['Low T' Television Ads Linked to Surge in Testosterone Use](#)

**March 21, 2017**

Men who see more ads for low testosterone or "low T" on local television channels may be more likely to seek tests or treatments to boost their levels of the hormone, a U.S. study suggests. Testosterone levels naturally decline with age, and some men with extremely small amounts of the hormone may be diagnosed with what's known as hypogonadism and prescribed needed testosterone therapy, researchers note in JAMA.

Source: [reuters.com](#)

### [Could OTC Medicines be the Answer to Alcoholism?](#)

**March 21, 2017**

The U.S. Food and Drug Administration (FDA) expanded the approval of steroid-free Spiriva Respimat (tiotropium bromide) for the maintenance treatment of asthma in children ages 6 and older. The FDA approved the supplemental new drug application (sNDA) under priority review status due to the latest clinical trial results conducted by Boehringer Ingelheim, the drug's manufacturer.

Source: [lungdiseasenews.com](#)

### [Many at Risk for Stroke Don't Get Anti-Clotting Drugs](#)

**March 15, 2017**

More than four in five stroke patients with a history of heart rhythm problems didn't get any blood thinners, or didn't take enough to help prevent a stroke before they had one, a U.S. study suggests.

Most strokes occur when a clot blocks an artery carrying blood to the brain, known as an ischemic stroke. The study focused on more than 94,000 stroke patients with atrial fibrillation, an irregular rapid heartbeat that can lead to stroke, heart failure and chronic fatigue.

Source: reuters.com

### **J&J and Bayer's Xarelto Cuts Recurrence of Dangerous Blood Clots in Study**

**March 18, 2017**

Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major bleeding compared with low dose aspirin in patients at elevated risk, according to data presented on Saturday.

Source: reuters.com

### **Cholesterol Drug Prevents Heart Attacks — but Costs \$14K a Year**

**March 17, 2017**

For the first time, research shows that a pricey new medication called Repatha not only dramatically lowers LDL cholesterol, the “bad” kind, it also reduces a patient's risk of dying or being hospitalized. Repatha, a man-made antibody also known as evolocumab, cut the combined risk of heart attack, stroke and cardiovascular-related death in patients with heart disease by 20%, a finding that could lead more people to take the drug, according to a study presented Friday at a meeting of the American College of Cardiology.

Source: usatoday.com

### **Higher Rate of Second Heart Attacks in Patients Who Can't Tolerate Statins**

**March 15, 2017**

After a heart attack, taking one of the drugs known as statins can lower the risk of a second attack, but for people who go off statins because of side effects, that risk rises again sharply, researchers say. In a study of more than 105,000 older Americans who had one heart attack, those who couldn't tolerate statins were 50 percent more likely than those who stayed on statins to have a second heart attack.

Source: reuters.com

### **This Prescription Drug Is Implicated In Almost A Third Of All Opioid Overdose Deaths**

**March 15, 2017**

Opioid overdose deaths are at a record high in the U.S., and deaths from prescription painkillers, including oxycodone, hydrocodone and methadone, are implicated in almost half of all cases. Less well known is the fact that benzodiazepines, such as Xanax and Valium, prescription tranquilizers used to treat anxiety, insomnia and seizures, are involved in about 30 percent of those prescription opioid deaths, perhaps due to deadly interactions.

Source: huffingtonpost.com

### **Opioid Dependence Can Start in Just a Few Days**

**March 16, 2017**

Doctors who limit the supply of opioids they prescribe to three days or less may help patients avoid the dangers of dependence and addiction, a new study suggests. Among patients without cancer, a single day's supply of a narcotic painkiller can result in 6 percent of patients being on an opioid a year later, the researchers said.

Source: healthday.com

### **FDA Issues Warning on IBS Drug Viberzi**

**March 15, 2017**

Patients who have undergone cholecystectomy should not receive the irritable bowel syndrome (IBS) drug eluxadoline (Viberzi) because of the potential for severe pancreatitis, the FDA said Wednesday. "An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death," the agency said.

Source: medpagetoday.com

### **Federal Advisory Panels Agree Opana's Risks Outweigh Benefits**

**March 14, 2017**

In a move that could lead to a national ban, two federal advisory panels voted Tuesday that the risks outweigh the benefits of a widely-abused opioid that was reformulated to deter addicts from snorting it. The new extended-release version of Endo Pharmaceuticals' Opana may even be more dangerous than the version it replaced, according to critics including the advocacy group Public Citizen. Two Food and Drug Administration advisory panels seemed to agree, voting 18 to 8 that it presents more risks than benefits to society.

Source: usatoday.com

### **Leukemia Drug Fends off Cancer for a Decade, Study Shows**

**March 9, 2017**

The cancer drug Gleevec appears to keep chronic myeloid leukemia at bay a decade into treatment -- with no signs of additional safety risks, a new study finds. Gleevec -- known generically as imatinib -- was hailed as a "wonder drug" when it was introduced in 2001 for treating chronic myeloid leukemia (CML).

Source: cbsnews.com

### **Nonclinical Factors Drive Antibiotic Choice in Pediatric CAP**

**March 9, 2017**

For children with community-acquired pneumonia (CAP), patient and nonclinical characteristics are associated with receipt of macrolides and broad-spectrum antibiotics versus amoxicillin, according to a study published online March 7 in Pediatrics.

Source: physiciansbriefing.com

### **Deadly Fungal Infection that Doctors Have been Fearing Now Reported in U.S.**

**March 10, 2017**

Nearly three dozen people in the United States have been diagnosed with a deadly and highly drug-resistant fungal infection since federal health officials first warned U.S. clinicians last June to be on the lookout for the emerging pathogen that has been spreading around the world.

Source: washingtonpost.com

### **With Same Training, Insulin Pumps no Better than Injections**

**March 10, 2017**

Nearly three dozen people in the United States have been diagnosed with a deadly and highly drug-resistant fungal infection since federal health officials first warned U.S. clinicians last June to be on the lookout for the emerging pathogen that has been spreading around the world.

Source: washingtonpost.com

### **Avoid Washing Down Levothyroxine with This Drink**

**April 3, 2017**

The absorption of oral levothyroxine, when taken with cow's milk, was found to be significantly reduced, according to findings presented at ENDO 2017. Levothyroxine is indicated for patients with hypothyroidism to replace the natural thyroid hormone thyroxine (T4) that is too low, or for patients with thyroid cancer, to suppress their thyroid stimulating hormone levels.

Source: empr.com

### **CDC: Medicaid Preferred Drug List Policies May Affect Methadone Overdose Rates**

**April 4, 2017**

A study published in the CDC's Morbidity and Mortality Weekly Report aimed to determine whether a decline in methadone-related deaths was related to the Medicaid reimbursement policies designed to reduce methadone prescribing.

Source: pharmacytimes.com

### [The Full Extent of Antibiotic Use in the United States? No One Knows.](#)

**March 31, 2017**

The threat of a post-antibiotic world, where the drugs to treat infectious diseases lose their effectiveness, draws ever closer, bringing an increased awareness in the health-care world about prescribing rates. But the available information about current usage rates and patterns isn't nearly good enough.

Source: modernmedicine.com

### [School Nurses Now Stock Heroin Antidote](#)

**March 30, 2017**

At every school in New Rochelle, New York, just north of the Bronx, in Westchester, there is a locked medicine cabinet in the nurse's office, stocked with things like EpiPens for allergic reactions, inhalers for asthma, Tylenol for aches and pains.

Source: bendbulletin.com

### [Heroin Epidemic Expands Its Grip on America](#)

**March 29, 2017**

Heroin use in the United States jumped fivefold over a decade, and young, white males are the epidemic's most likely victims, a new study finds. One addiction specialist blamed the lax use of prescription opioid painkillers -- narcotics such as Oxycontin, Percocet and Vicodin -- for the surge in heroin use.

Source: healthday.com

### [FDA approvals for specialty drugs to pick up in 2017](#)

**March 29, 2017**

The specialty drugs market is seeing increased competition and important advances in cancer and orphan drug development, including specialty generics and biosimilars, according to an update presented at the AMCP Managed Care & Specialty Pharmacy Annual Meeting in Denver.

Source: managedhealthcareexecutive.modernmedicine.com

### [HPV Vaccine Could Protect More People With Fewer Doses, Doctors Insist](#)

**March 29, 2017**

You'd think that a vaccine that protects people against more than a half dozen types of cancer would have patients lining up to get it. But the human papillomavirus (HPV) vaccine, which can prevent roughly 90 percent of all cervical cancers as well as other cancers and sexually transmitted infections caused by the virus, has faced an uphill climb since its introduction more than a decade ago.

Source: npr.org

### **The Drug Overdose Epidemic in America's Suburbs**

**March 29, 2017**

A decade ago the suburbs were the safest place in America when it came to the number of drug overdoses. Now they're the most dangerous. That's one finding in a shocking report released Wednesday. "This has been a very dark report," says Marjory Givens, one of the authors of the 2017 County Health Rankings. She is deputy director of data and science for the project as well as an associate scientist at the University of Wisconsin's Population Health Institute. "We're facing a crisis here."

Source: bloomberg.com

### **Study Suggests Heartburn Meds-Superbug Infections Link**

**March 27, 2017**

Patients who take certain heartburn medications may be more likely to suffer recurrent bouts of a common "superbug" infection, a new study suggests. Proton pump inhibitors, such as Prilosec, Prevacid and Nexium, or so-called H2 blockers, such as Zantac, Pepcid and Tagamet, were linked to a 50 percent increased risk of developing multiple Clostridium difficile infections, researchers found.

Source: healthday.com



## RECALLS

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	Montelukast sodium tablets, 10 mg, 30-count bottle, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, By: HETERO Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar - 509 301, India, NDC 31722-726-30	Class III	Lot # MON16001B, Exp 01/18	Discoloration: the firm received a complaint of a sealed bottle in which tablets inside had blue spots and a blue powder inside the bottle.	Hetero USA Inc 1035 Centennial Ave Piscataway, NJ 08854-4124
Drugs	Sensodyne Repair & Protect Whitening, (stannous fluoride 0.45% (0.15% w/v fluoride ion)), Net Wt. 3.4 oz, Distributed by Glaxo SmithKline Consumer Healthcare LP Moon Township PA 15108 --- NDC 0135-0575-01, UPC UPC: 3 10158 84060 2	Class II	A6J231, expiration 08/2018; A6J261, expiration 08/2018; A6K171, expiration 08/2018; A6K241, expiration, 09/2018; A6M231, expiration 10/2018	Presence of Foreign Substance; low concentration of an additional flavoring ingredient, Patchouli oil resulting in complaints of off flavor/scent	GSK Consumer Healthcare 184 Liberty Corner Rd Ste 200 Warren, NJ 07059-6868
Drugs	Ciprofloxacin in Dextrose (5%) Injection, USP, 400 mg in 200 mL 5% Dextrose, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-009-24	Class II	Lot #: A051288, Exp. Sep 2 017	Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.	Claris Lifesciences Inc 1445 US Highway 130 North Brunswick, NJ 08902-3100
Drugs	Fluconazole Injection, USP, 400 mg in 200 mL, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-003-06	Class II	Lot #: A051052, Exp. Aug 2017	Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.	Claris Lifesciences Inc 1445 US Highway 130 North Brunswick, NJ 08902-3100
Drugs	Levofloxacin Injection in 5% Dextrose, 750 mg in 150 mL 5% Dextrose, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-048-24	Class II	Lot #: A060040, Exp. Dec 2 017	Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.	Claris Lifesciences Inc 1445 US Highway 130 North Brunswick, NJ 08902-3100
Drugs	Metronidazole Injection, USP, 500 mg/100 mL, Rx only, Manufactured for: Claris Lifesciences Inc. North Brunswick NJ, 08902, By: Claris Injectable Ltd. Gujarat, India, NDC 36000-001-24	Class II	Lot #: A060205; A060209, Exp. Jan 2018	Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.	Claris Lifesciences Inc 1445 US Highway 130 North Brunswick, NJ 08902-3100

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	Divalproex Sodium Delayed Release Tablets, USP, 500 mg, a) 100 count (NDC 68382-033-01) and b) 500 count (NDC 68382-033-05) bottles, Rx only, manufactured by Cadila Healthcare Ltd, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals, Pennington, NJ	Class II	a) MR8221, MR8222 exp 7/31/2017; MR10260, exp 9/30/2017; MR10926, exp 10/31/2017; b) MR6187, exp 5/31/2017; MR7302, exp 6/30/2017; MR7768, MR7769, exp 7/31/2017; MR8247, exp 7/31/2017; MR8887, MR8892, MR8893 exp 8/31/2017; MR9014, MR10414 exp 9/30/2017; MR10928, exp 10/31/2017; MR11183, MR11185, MR11186, exp 11/30/2017	Failed Dissolution Specifications; 9 month long term stability	Zydus Pharmaceuticals USA Inc 73 Route 31 N Pennington, NJ 08534-3601
Drugs	Atorvastatin Calcium Tablets, 10 mg*, packaged in a) 90-count bottles (NDC 0378-3950-77); b) 90-count bottles (NDC 0378-3950-09); c) 500-count bottles (NDC 0378-3950-05); d) 500-count bottles (NDC 0378-3950-07), Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.	Class II	Lot #: a) 3076141, 3076142, Exp 05/18; 2007223, Exp 06/18; 2007335, Exp 07/18; 2007336, Exp 08/18; 2007446, 3084691, Exp 09/18; 3084692, Exp 01/18; b) 3073773, Exp 01/18; 2007445, Exp 09/18; c) 3076139, 3076140, 3076143, Exp 05/18; 3076144, 3076145, Exp 06/18; 2007445, Exp 09/18; d) 3070837, Exp 10/17; 3073773, Exp 01/18;	Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.	Mylan Pharmaceuticals Inc. 781 Chestnut Ridge Rd Morgantown, WV 26505-2730
Drugs	Atorvastatin Calcium Tablets, 20 mg*, packaged in a) 90-count bottles (NDC 0378-3951-09) and b) 500-count bottles (NDC 0378-3951-07); Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.	Class II	Lot #: a) 3073776, Exp 01/18; 3073777, 3074909, Exp 02/18; 3075564, 3075565, Exp 03/18; 2007338, Exp 08/18; b) 3070838, Exp 10/17; 3073775, Exp 01/18; 3074908, 3074909, Exp 02/18; 3075564, Exp 03/18; 2007224, 3075887, Exp 06/18; 2007337, 2007338, Exp 08/18	Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.	Mylan Pharmaceuticals Inc. 781 Chestnut Ridge Rd Morgantown, WV 26505-2730
Drugs	Atorvastatin Calcium Tablets, 40 mg*, packaged in a) 90-count bottles (NDC 0378-3952-09) and b) 500-count bottles (NDC 0378-3952-07); Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.	Class II	Lot #: a) 3073779, 3073780, Exp 02/18; 3074910, Exp 03/18; 3075568, Exp 04/18; 3075889, 3075890, Exp 06/18; 2007339, 2007340, Exp 08/18; 3079881, 3079882, Exp 10/18; b) 3070839, Exp 10/17; 3073778, 3073779, Exp 02/18; 3075566, 3075567, Exp 04/18; 3075890, 2007225, Exp 06/18; 2007340, Exp 08/18; 3079880, 3079881, Exp 10	Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.	Mylan Pharmaceuticals Inc. 781 Chestnut Ridge Rd Morgantown, WV 26505-2730

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
			/18		
Drugs	Atorvastatin Calcium Tablets, 80 mg*, packaged in a) 90-count bottles (NDC 0378-3953-09) and b) 500-count bottles (NDC 0378-3953-07), Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.	Class II	Lot #: a) 3073782, 3073783, Exp 02/18; 3074915, 3074916, 3074917, Exp 03/18; 3074918, 3075572, Exp 04/18; 3075573, 3075574, Exp 05/18; 2007226, 3075894, Exp 06/18; 2007344, 2007345, 2007346, Exp 08/18; 2007451, 2007452, 2007453, 2007454, Exp 09/18; b) 3070840, Exp 10/17; 3073781, 3074911, Exp 02/18; 3074912, 3074913, 3074914, Exp 03/18; 3075570, 3075571	Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.	Mylan Pharmaceuticals Inc. 781 Chestnut Ridge Rd Morgantown, WV 26505-2730
Drugs	Atorvastatin Calcium Tablets, 10 mg*, 100-count Unit Dose Tablets (10 x 10) per carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., NDC 51079-208-20	Class II	Lot #: 3084288, Exp. 07/18	Microbial Contamination of Non-Sterile Products: potential of an elevated bioburden with identification of objectionable organisms.	Mylan Institutional, Inc. (d.b.a. UDL Laboratories) 1718 Northrock Ct Rockford, IL 61103-1201
Drugs	Vancomycin Hydrochloride for Injection, USP, 10 grams, Pharmacy Bulk Package - Not For Direct Infusion, For Intravenous Use, packaged in 100 mL glass vial, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-6510-01	Class I	Lot # 591053A, Exp 11/1/2017	Presence of Particulate Matter: A hair was found stuck to the stopper of inside a single vial. The hair came in contact with the reconstituted drug product.	Hospira Inc., A Pfizer Company 275 N Field Dr Lake Forest, IL 60045-2579
Drugs	Vancomycin HCl 1.25 g added to 5% Dextrose 250 mL Bag For IV Use Only, Rx Only, SCA Pharmaceuticals, Little Rock, AR 72205, NDC 70004-0922-40	Class I	Lot: 20161221@70, Exp 02/04/2017	Presence of particulate matter - this recall is due to a recent Hospira recall of vancomycin hydrochloride 10gm vials due to presence of particulate matter.	SCA Pharmaceuticals 8821 Knoedl Ct Little Rock, AR 72205-4600
Drugs	Vancomycin HCl 1 g added to 0.9% Sodium Chloride 250 mL Bag For IV Use Only, Rx Only, SCA Pharmaceuticals, Little Rock, AR 72205, NDC 70004-0920-59	Class I	Lot: 20161228@65, Exp 02/26/2017; Lot: 20161214@76, Exp 02/12/2017	Presence of particulate matter - this recall is due to a recent Hospira recall of vancomycin hydrochloride 10gm vials due to presence of particulate matter.	SCA Pharmaceuticals 8821 Knoedl Ct Little Rock, AR 72205-4600
Drugs	Vancomycin HCl 1.25 g added to 0.9% Sodium Chloride 250 mL Bag For IV Use Only, Rx Only, SCA Pharmaceuticals, Little Rock, AR	Class I	Lot: 20161213@23, Exp 2/11/2017; Lot: 20161214@80, Exp 2/12/2017; Lot: 20161215@1, Exp 2/13/2017	Presence of particulate matter - this recall is due to a recent Hospira recall of vancomycin hydrochloride	SCA Pharmaceuticals 8821 Knoedl Ct Little Rock, AR

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	72205, NDC 70004-0923-59		7	10gm vials due to presence of particulate matter.	72205-4600
Drugs	Vancomycin HCl 1.5 g added to 0.9% Sodium Chloride 250 mL Bag For IV Use Only Rx Only, SCA Pharmaceuticals, Little Rock, AR 72205, NDC 70004-0924-59	Class I	Lot: 20161212@44, Exp 2/10/2017; Lot: 20161230@40, Exp 2/28/2017	Presence of particulate matter - this recall is due to a recent Hospira recall of vancomycin hydrochloride 10gm vials due to presence of particulate matter.	SCA Pharmaceuticals 8821 Knoedl Ct Little Rock, AR 72205-4600
Drugs	Vancomycin HCl 1.5 gram added to 5% Dextrose 500 mL Total Approximate Volume 515 mL For IV Use Only, Rx Only, SCA Pharmaceuticals, Little Rock, AR 72205, NDC 70004-0925-44	Class I	Lot: 20161221@74, Exp 2/4/2017	Presence of particulate matter - this recall is due to a recent Hospira recall of vancomycin hydrochloride 10gm vials due to presence of particulate matter.	SCA Pharmaceuticals 8821 Knoedl Ct Little Rock, AR 72205-4600
Drugs	Vancomycin HCl 750 mg added to 250 mL 0.9% Sodium Chloride For IV Use Only, Rx Only, SCA Pharmaceuticals, Little Rock, AR 72205, NDC 70004-0929-40	Class I	Lot: 20161222@8, Exp 2/5/2017	Presence of particulate matter - this recall is due to a recent Hospira recall of vancomycin hydrochloride 10gm vials due to presence of particulate matter.	SCA Pharmaceuticals 8821 Knoedl Ct Little Rock, AR 72205-4600
Drugs	Vancomycin HCl 750 mg added to 5% Dextrose 250 mL For IV Use Only, Rx Only, SCA Pharmaceuticals, Little Rock, AR 72205, NDC 70004-0918-40	Class I	Lot: 20161219@3, Exp 2/2/2017	Presence of particulate matter - this recall is due to a recent Hospira recall of vancomycin hydrochloride 10gm vials due to presence of particulate matter.	SCA Pharmaceuticals 8821 Knoedl Ct Little Rock, AR 72205-4600
Drugs	Ibuprofen Lysine Injection, 20 mg/2 mL (10 mg/mL), 2 mL Single-Dose Vial (NDC 39822-1030-1), packaged in 3 x 2 mL Single-Dose Vials per carton (NDC 39822-1030-2); Rx only, Distributed by: X-Gen Pharmaceuticals, Inc., Big Flats, NY 14814; Manufactured by: Exela Pharma Sciences, LLC, Lenoir, NC 28645.	Class I	PLND1613, Exp 02/18	Presence of Particulate Matter	X-Gen Pharmaceuticals Inc. 300 Daniel Zenker Dr Horseheads, NY 14845-1014
Drugs	XtraHRD Natural Male Enhancement Capsules, Herbal Dietary Supplement, 500 mg capsules, 2, 4 and 10 count boxes, Made in Malaysia, Distributed by Naturally Hard Supplements, Reno, NV 89503, UPC 680474228768	Class I	All lots	Marketed without an Approved NDA/ANDA: Product contains N-desmethyl tadalafil an analogue to tadalafil which is an active pharmaceutical ingredient in a FDA approved drug used to treat erectile	Organic Herbal Supply 8303 Sierra College Blvd Ste 128 Roseville, CA 95661-9420

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
				dysfunction (ED).	
Drugs	Nifedipine Extended-Release Tablets, 30 mg, 100-count bottles, Rx Only, Manufactured for Alvogen Inc. Pine Brook, NJ 07058 USA, NDC 47781-368-01.	Class III	Lot #: BXH1P22, BXH1P21 A, BXH1P21, BXH1P31, BXH1P21B, Exp. 11/2017; BXH6EL1, BXH66A1, BXH6EN1, BXH6EP1, BXH6ER1, Exp. 06/2018; BXH81K1A, BXHBJD1A, Exp. 10/2018	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60	Class III	Lot #C607323, Exp 10/18	Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.	Dr. Reddy's Laboratories, Inc. 107 College Rd E Princeton, NJ 08540-6623
Drugs	Cotellic (cobimetinib) Tablets, 20 mg, 63 count bottle, Rx Only, Made in Switzerland. Distributed by Genentech USA, Inc., South Francisco, CA. 94080, NDC 50242-717-01,UPC 3 50242-717-01.	Class II	B1009MC, B1009M9, B1009MA; Exp. 02/18 B1009MT 02/19	Superpotent Drug: An oversized tablet was found in a bottle.	Genentech Inc. 1 Dna Way South San Francisco, CA 94080-4990
Drugs	Fluphenazine Decanoate Injection, USP; 25 mg/mL, 5mL vials, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173, NDC 63323-0272-05	Class III	Lot #: 6111141, Exp. 07/17; 6111222, Exp. 08/17; 6112346, Exp. 01/18; 6112725, Exp. 03/18	Subpotent Drug	Fresenius Kabi USA, LLC 3 Corporate Dr Lake Zurich, IL 60047-8930
Drugs	Kalbitor (ecallantide), 10mg/mL, packaged in 3 vials per Carton, Rx Only, Dynax Corp., Burlington, MA. NDC47783-101-01	Class II	Lot #: A1500009, Exp. Jan 31, 2019	Presence of Particulate Matter: Glass	Shire 300-400 Shire Way Lexington, MA 02421-2101
Drugs	Adalat CC (nifedipine) Extended Release Tablets 30 mg, 100-count bottles, Rx only, Manufactured for Bayer Healthcare Bayer Healthcare Pharmaceuticals Inc. Whippany, NJ 07901 Manufactured in Germany, NDC 50419-701-05	Class III	Lot #: BXH1P21A, Exp. 11/2017	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	Adalat CC (nifedipine) Extended Release Tablets, 60 mg, 100- count bottles, Rx only Manufactured for Almatica, Almatica Pharma Inc. Pinebrook, NJ 07058 USA, NDC	Class III	Lot #: BXH1BE1A, BXH1P41A, Exp. 01/2018.	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	50419-702-05				07058-9743
Drugs	Ciclopirox Olamine Cream USP, 0.77%, packaged in a) 15 g tubes (NDC 0713-0638-15), b) 30 g tubes (NDC 0713-0638-31), and c) 90 g tubes (NDC 0713-0638-18), Rx only, Manufactured by: G&W Laboratories, Inc., South Plainfield, NJ 07080.	Class III	Lot #: a) 63800090, Exp 04/17; 63800095, Exp 11/17; 1000573, Exp 02/18; 1002560, Exp 06/18; b) 63800090, Exp 04/17; 63800092, Exp 07/17; 63800093, Exp 08/17; 63800095, Exp 11/17; 1000574, Exp 02/18; 1001772, Exp 05/18; c) 63800089, Exp 03/17; 63800091, Exp 07/17; 63800094, Exp 08/17; 1000842, Exp 01/18; 1000966, Exp 03/18;	Labeling: Incorrect or Missing Package Insert: product lots packaged with an out-of-date insert.	G & W Laboratories, Inc. 111 Coolidge St South Plainfield, NJ 07080-3895
Drugs	Ventolin HFA (albuterol sulfate) Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations, Net Wt. 18 g inhalers, Rx only, GlaxoSmithKline, Research Triangle Park, NC 22709, NDC 0173-0682-20.	Class II	Lot #: 6ZP9848, Exp 03/18 ; 6ZP0003, 6ZP9944, Exp 04/18.	Defective Delivery System: Elevated number of units with out of specification results for leak rate.	GlaxoSmithKline, LLC 1011 N Arendell Ave Zebulon, NC 27597-2309
Drugs	Quinapril Tablets USP 5 mg, 90 count bottles, Lupin Pharmaceuticals, Inc., Baltimore, MD --- NDC 68180-556-09	Class III	Batch number G303703, exp 3/2016	Failed Impurities/Degradation Specifications; Impurity A	Lupin Pharmaceuticals Inc. 111 S Calvert St Fl 21ST Baltimore, MD 21202-6174
Drugs	Nifedipine Extended-Release Tablets, 60 mg, 100-count bottles, Rx Only, Manufactured for Alvogen Inc. Pine Brook, NJ 07058 USA, NDC 47781-369-01.	Class III	Lot #: BXH1P41, BXH1BEE1, BXH1BE2, BXH1BE1B, BXH1BE1A, BXH1P41A, Exp. 01/2018; BXH81R1, BXHB D41A, BXH5ZR1, BXH9AL1 A, Exp. 06/2018; BXHCUD 1A, BXHCUF2A, Exp. 01/2019.	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	Nifedipine Extended-Release Tablets, 90 mg, 100-count bottles, Rx Only, Manufactured for Alvogen Inc. Pine Brook, NJ 07058 USA, NDC 47781-370-01.	Class III	Lot #: BXH1P51, BXH66D1, BXH1P51A, BXH5ZS1, Exp. 03/2018; BXH1P52, Exp. 05/2018; BXHBF1A, and BXH8S1A, Exp. 10/2018.	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	Adalat CC (nifedipine) Extended-Release Tablets, 90 mg, 100-count bottles, Rx Only, Manufactured for Almatica Pharma Inc. Pine Brook, NJ	Class III	Lot #: BXH66D1A, Exp. 03/2018	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	07058 USA, NDC 50419-70305				07058-9743
Drugs	Adalat CC (nifedipine) Extended-Release Tablets, 30 mg, 100-count bottles, Rx Only, Manufactured for Almatica Pharma Inc. Pine Brook, NJ 07058 USA, NDC 5242749401	Class III	Lot #: BXHBJD1A, Exp. 10/2018	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	Adalat CC (nifedipine) Extended-Release Tablets, 90 mg, 100-count bottles, Rx Only, Manufactured for Almatica Pharma Inc. Pine Brook, NJ 07058 USA, NDC 5242749401	Class III	Lot #: BXHBJD1A, Exp. 10/2018	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	Adalat CC (nifedipine) Extended-Release Tablets, 60 mg, 100-count bottles, Rx Only, Manufactured for Almatica Pharma Inc. Pine Brook, NJ 07058 USA, NDC 5242749501	Class III	Lot #: BXCUE1A, Exp. 01/2019	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	Adalat CC (nifedipine) Extended-Release Tablets, 90 mg, 100-count bottles, Rx Only, Manufactured for Almatica Pharma Inc. Pine Brook, NJ 07058 USA, NDC 5242749601	Class III	Lot #: BXHD7U1A, Exp. 10/2018	Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib	Alvogen, Inc 10 Bloomfield Ave Bldg B Ste 2 Pine Brook, NJ 07058-9743
Drugs	Fluocinolone Acetonide Topical Solution USP 0.01% For Topical Use Only, Not for Ophthalmic Use, 60 mL bottle, Rx Only, Manufactured for Gavis Pharmaceuticals, LLC, Somerset NJ 08873, Manufactured by Novel Laboratories, Inc. Somerset, NJ 08873, NDC 43386-069-60	Class III	Lot # M15496; Exp. 10/17 Lot # M15507; Exp. 12/17	Chemical Contamination	Novel Laboratories, Inc. 390 & 400 Campus Drive Somerset, NJ 08873-1145
Drugs	Double Hyaluronic 1000, 'AN OUNCE OF GOLD' Volumizing Day Cream, Broad Spectrum SPF 30+, (Octinoxate 7.725%, Oxybenzone 6.18%, Octisalate 5.15%, Avobenzone 3.09%), Net Wt. 1.8 oz. (51 g) jar, Distributed by Signature Club A, Ltd, Tampa, FL 33609.	Class II	Lot #: 1626253/1746. Exp 10/18	Microbial Contamination of Non-Sterile Products: odor complaint of product due to microbial contamination.	Signature Club A Ltd 550 N Reo St Ste 300 Tampa, FL 33609- 1037
Drugs	LATANOPROST OPHTHALMIC SOLUTION, 0.005%, 125 ug/2.5 mL, packaged in 2.5 mL bottle, Rx only, Manufactured for: Akorn, Inc., Lake	Class II	Lot # LAB15G52, LAB11G52, Exp 6/17; LAB18I52, Exp 8/17; LAB9L52, 11/17; LAB1A62, LAB9A62, Exp 12/	Lack of assurance of sterility: product was found to be empty, under-filled, or leaking.	Akorn, Inc. 1925 W Field Ct Ste 300 Lake Forest, IL



Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	Forest, IL 60045, NDC 17478-625-12		17		60045-4862
Drugs	Penicillin V Potassium Tablets, USP 500 mg (800,000 units) 1000 count bottles, Rx Only, Distributed by: Citron Pharma LLC, East Brunswick, NJ --- NDC 57237-041-99	Class III	Batch Numbers: PE501506 9-A, exp 11/2018	Presence of Foreign Tablet/Capsule; Amoxicillin 500 mg was found in bottles of Penicillin V potassium 500 mg	Citron Pharma Llc 2 Tower Center Blvd Ste 1101 East Brunswick, NJ 08816-1100
Drugs	Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allergan Irvine, CA 92612, NDC 0023-3205-08.	Class III	Lot #: 92577, Exp. JUN 2018	Failed Impurities/Degradation Specifications	Allergan Sales, LLC 8301 Mars Dr Waco, TX 76712-6578
Drugs	Doxercalciferol Capsules 0.5mcg, 50 count bottles, Rx, only, Manufactured by Cipla Limited Kurkumbh, Maharashtra, India, Manufactured for West-Ward, Pharmaceuticals, Corp., Eatontown, NJ -- NDC 0054-0338-19	Class III	Lot KB60707, 10/31/2018	Failed Tablet/Capsule Specifications; during an internal inspection, capsules were found with illegible print.	West-Ward Columbus, Inc. 1809 Wilson Rd Columbus, OH 43228-9579
Drugs	hydrALAZINE HYDROCHLORIDE INJECTION, USP, 20 mg/mL, 1 mL Single Dose Vial, packaged in 25 Vials per carton, Rx only, APP Fresenius Kabi USA, LLC, Lake Surich, IL 60047, NDC 63323-614-01, Distributed by McKesson Medical-Surgical, Inc.	Class II	Lot #s: 6114311, 6114717, Exp 05/18	Temperature Abuse: Certain pieces of these lots distributed by McKesson Medical Surgical Inc. were inadvertently stored refrigerated rather than the labeled room temperature recommendation.	Mckesson Medical Surgical 9954 Mayland Dr Henrico, VA 23233-1464
Drugs	ESTRIOL, USP (Micronized) Bulk, in a) 5 grams (NDC 38779-0732-03), b) 25 grams (NDC 38779-0732-04), c) 100 grams (NDC 38779-0732-05), and d) 1 Kg (NDC 38779-0732-09) bottles, Packed by MEDISCA, INC. PLATTSBURGH, NY 12901; Product Code 0732	Class II	a) 126317/D,126317/F,127288/C, 127296/D, 136212/C, 137155/C,137156/C, 138638/C,138646/B, 138646/E, 138646/I b) 126317/C, 126317/E, 127288/B, 127296/C, 136212/B, 137155/B, 137156/B, 138638/B, 138646/A, 138646/D,138646/H c) 126317/B,127288/A,127296/B, 136212/A, 137155/A, 137156/A,138638/A, 138646/C, 138646/G, 141219/A d) 126317/A, 127296/A, 138646/F	cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection	Medisca, Inc. 661 State Route 3 Unit C Plattsburgh, NY 12901-6531
Drugs	ESTRONE, USP Bulk, in a) 100 mgs (NDC 38779-0891-05), b) 1 gram (NDC 38779-0891-06), c) 5 grams (NDC 38779-0891-03), d) 25 grams (NDC 38779-0891-04), and e) 100 grams (NDC 38779-0891-09) Bottles,	Class II	a) 124880/D,124880/O, 130940/J, 135312/E b) 124880/C 124880/F 124880/I 124880/N 130940/D 130940/I 135312/D 135312/I 136546/D 139489/B c) 124	cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a	Medisca, Inc. 661 State Route 3 Unit C Plattsburgh, NY



Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	Packed by MEDISCA INC. PLATTSBURGH, NY 12901; Product Code 0891		880/B, 124880/H, 124880/M, 130940/C, 130940/H, 135312/C, 135312/H, 136546/C d) 124880/A ,130940/B, 130940/G, 135312/B, 135312/G, 136546/B, 139489/A e) 124880/G, 124880/J, 124880/L,130940/A, 130940/F,	recent FDA inspection	12901-6531
Drugs	ESTRADIOL, USP (Hemihydrate)(Micronized), in a) 100 mg (NDC 38779-0869-07), b) 1 g (NDC 38779-0869-06), c) 5 g (NDC 38779-0869-03), d) 10 g (NDC 38779-0869-01), e) 25 g (NDC 38779-0869-04), f) 100 g (NDC 38779-0869-05) , g) 500 g (NDC 38779-0869-08), h) 1 Kg (NDC 38779-0869-09) bottles, Packed by MEDISCA	Class II	a) 137169/F b) 129670/G, 129670/K, 130942/G, 130942/L, 131429/G, 131430/G, 137169/E c) 129670/F, 129670/J, 130942/F, 130942/K 131429/F, 131430/F, 137169/D, d) 129670/E, 129670/I,130942/E, 130942/J,131429/E, 131430/E, 137169/C e) 129670/D, 129670/H, 130942/D, 130942/I, 131429/D, 131430/D, 131430/H, 137169/B f) 129670/C, 130942/C, 130942/H, 131429/C, 131430/C, 137169/A, 137169/F g)	cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection	Medisca, Inc. 661 State Route 3 Unit C Plattsburgh, NY 12901-6531
Drugs	ESTRADIOL, USP Bulk (Hemihydrate), in a) 25 g (NDC 38779-2261-04) and b) 100 g (NDC 38779-2261-05) bottles, Packed by MEDISCA INC. PLATTSBURGH, NY Product Code 2261	Class II	a) 129669/C, 129669/F, 129669/H, 129669/J, 130941/B 130941/D, 130941/F, 136108/B, 139091/B; b) 129669/B, 129669/E, 130941/A, 130941/C, 130941/E ,130941/G, 136108/A,	cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection	Medisca, Inc. 661 State Route 3 Unit C Plattsburgh, NY 12901-6531
Drugs	Estradiol Micronized Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd, Qinhuangdao 066004, China (NDC 44132-001-01) (44132-001-06)	Class II	Batch 80001512002 to Batch 80801604003, exp 10/22/2017 through 3/30/3018	cGMP Deviations; lack of quality assurance.	Qinhuangdao Zizhu Pharmaceutical, Co. No 10, Longhai Road Economic & Technological Development Zon Qinhuangdao
Drugs	Estradiol Non-Micronized, USP, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd, Qinhuangdao 066004, China	Class II	Batch 80701510001 to Batch 80001607002, exp 10/22/2017 through 7/5/2018	cGMP Deviations; lack of quality assurance.	Qinhuangdao Zizhu Pharmaceutical, Co. No 10, Longhai Road Economic & Technological Development Zon Qinhuangdao

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
Drugs	Estriol Micronized, USP, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd, Qinhuangdao 066004, China 44132-007-06	Class II	Batch 81801504002 to 81801701003, exp 4/12/2017 through 1/19/2019	cGMP Deviations; lack of quality assurance.	Qinhuangdao Zizhu Pharmaceutical, Co. No 10, Longhai Road Economic & Technological Development Zon Qinhuangdao
Drugs	Estrone Micronized, USP, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd., Qinhuangdao 066004, China (NDC 44132-003-04) (NDC 44132-003-02)(NDC 44132-003-06)	Class II	Batch 82801505001 to 82801606001, exp 5/4/2017 through 5/19/2018	cGMP Deviations; lack of quality assurance.	Qinhuangdao Zizhu Pharmaceutical, Co. No 10, Longhai Road Economic & Technological Development Zon Qinhuangdao
Drugs	Testosterone Micronized, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd., Qinhuangdao 066004, China (NDC 44132-006-06)	Class II	Batch 78801507001 to 78901612003, exp 6/22/2017 through 11/21/2018	cGMP Deviations; lack of quality assurance.	Qinhuangdao Zizhu Pharmaceutical, Co. No 10, Longhai Road Economic & Technological Development Zon Qinhuangdao
Drugs	Ethinyl Estradiol Micronized, USP, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd, Qinhuangdao 066004, China (NDC 44132-002-05)	Class II	Batch 73801506007 to 73801603001, exp 5/31/2017 through 1/15/2018	cGMP Deviations; lack of quality assurance.	Qinhuangdao Zizhu Pharmaceutical, Co. No 10, Longhai Road Economic & Technological Development Zon Qinhuangdao
Drugs	Levonorgestrel Non-Micronized, USP, Bulk, Rx only, For Prescription Compounding, Manufactured by Qinhuangdao Zizhu Pharmaceutical Co., Ltd., Qinhuangdao 066004, China (NDC 44132-012-01),	Class II	Batch 70001602009, 2/21/2021	cGMP Deviations; lack of quality assurance.	Qinhuangdao Zizhu Pharmaceutical, Co. No 10, Longhai Road Economic & Technological Development Zon Qinhuangdao
Drugs	BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 100 mg,	Class	Lot #: a) BU15001B, BU15003D, Exp 12/16; b) BU1	Failed Impurities/Degradation	Jubilant Cadista Pharmaceuticals,

Product Type	Product Description	Class	Code Information	Reason for Recall	Recalling Firm
	packaged in a) 60-count bottles (NDC 59746-315-60) and b) 100-count bottles (NDC 59746-315-01), Rx only, Manufactured by: Jubilant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.	III	5002A, Exp 12/16	Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.	Inc. 207 Kiley Dr Salisbury, MD 21801-2249
Drugs	BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, packaged in a) 60-count bottles (NDC 59746-316-60) and b) 100-count bottles (NDC 59746-316-01), Rx only, Manufactured by: Jubilant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.	Class III	Lot #s: a) BU25001A, Exp 12/16; BU25002A, BU25003A, BU25004A, Exp 01/17; b) BU24003A, Exp 10/16; BU24004A, BU24005A, Exp 11/16; BU25005A, Exp 01/17	Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.	Jubilant Cadista Pharmaceuticals, Inc. 207 Kiley Dr Salisbury, MD 21801-2249
Drugs	BuPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, packaged in a) 60-count bottles (NDC 59746-317-60) and b) 100-count bottles (NDC 59746-317-01), Rx only, Manufactured by: Jubilant Life Sciences Ltd., Roorkee-247661, India; Marketed by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, USA.	Class III	Lot #s: a) BU34002A, BU34003A, Exp 11/16; b) BU34001A, Exp 10/16	Failed Impurities/Degradation Specifications: high out of specification results for one of the known degradation products, m-chlorobenzoic acid.	Jubilant Cadista Pharmaceuticals, Inc. 207 Kiley Dr Salisbury, MD 21801-2249

\*Please refer to FDA website for further information; <http://www.fda.gov/Safety/Recalls/EnforcementReports/default.htm>

# CURRENT DRUG SHORTAGES

---

## Ondansetron Injection

**March 21, 2017**

### Reason for the Shortage

- AuroMedics did not provide a reason for the shortage.
- Fresenius Kabi has ondansetron injection available.
- Heritage has ondansetron injection available.
- Mylan Institutional has ondansetron injection available.
- Novartis has Zofran injection available.
- Pfizer has ondansetron injection available.
- Sagent has ondansetron injection available.
- Teva discontinued ondansetron 2 mg/mL 20 mL vials. The 2 mL vials are available.
- West-Ward has ondansetron injection available.
- Wockhardt has ondansetron injection on an FDA import alert.

### Estimated Resupply Dates

- AuroMedics has ondansetron 2 mg/mL 2 mL and 20 mL vials on intermittent back order and the company is releasing product as it becomes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1040>

## Nitroglycerin Injection

**March 21, 2017**

### Reason for the Shortage

- American Regent did not provide a reason for the shortage.
- The premixed bags are not affected by this shortage.

### Estimated Resupply Dates

- American Regent has nitroglycerin 50 mg/mL 10 mL vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=786>

## Levocarnitine Oral Tablets and Solution

**March 21, 2017**

### Reason for the Shortage

- Akorn has levocarnitine tablets available.
- Sigma-Tau has Carnitor presentations on shortage due to increased demand.
- Rising Pharmaceuticals discontinued levocarnitine tablets in January 2017.

### Estimated Resupply Dates

- Akorn has levocarnitine oral solution on allocation.
- Sigma-Tau has Carnitor tablets on allocation.
- Sigma-Tau has Carnitor 100 mg/mL oral solution and Carnitor SF 100 mg/mL Sugar-Free oral solution on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1254>

### Haloperidol Decanoate Injection

March 21, 2017

#### Reason for the Shortage

- Teva is not actively marketing haloperidol decanoate.
- West-Ward is not actively marketing haloperidol decanoate injection.
- Fresenius Kabi had haloperidol decanoate on shortage due to short-term manufacturing delays.

#### Estimated Resupply Dates

- All marketed presentations are available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=526>

### Etoposide Injection

March 21, 2017

#### Reason for the Shortage

- Bristol-Myers Squibb did not provide a reason for the shortage of Etopophos.
- Etoposide solution for injection is not affected by this shortage.

#### Estimated Resupply Dates

- Bristol-Myers Squibb has Etopophos on back order and the company estimates a release date of July 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=652>

### Etomidate Injection

March 21, 2017

#### Reason for the Shortage

- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- Pfizer has Amidate on shortage due to manufacturing delays. Pfizer discontinued etomidate ampules in October 2016.
- Mylan cannot provide a reason for the current back order.
- Par Sterile Products discontinued etomidate in early 2015.
- Sagent is no longer marketing etomidate.
- Zydus has etomidate on shortage due to an increase in demand

#### Estimated Resupply Dates

- Pfizer has Amidate 20 mL LifeShield syringes on back order and the company cannot estimate a release date.
- West-Ward has etomidate 2 mg/mL 20 mL vials available with expiration date of December 2017.
- Zydus has etomidate 2 mg/mL 10 mL and 20 mL vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=419>

### Carboplatin Solution for Injection

March 21, 2017

#### Reason for the Shortage

- Bedford discontinued carboplatin in May, 2011 to concentrate on the manufacturing of other products.
- Fresenius Kabi has carboplatin available except for some short-dated product.

- Mylan Institutional cannot provide a reason for the shortage.
- Pfizer has carboplatin injection available.
- Sagent states the reason for the shortage is increased demand for the product and manufacturing delays.
- Sandoz has discontinued carboplatin injection.
- Teva has carboplatin available.

#### Estimated Resupply Dates

- Fresenius Kabi has carboplatin 45 mL vials available with an expiration date of <5 months.
- Mylan Institutional has all carboplatin injection on back order and the company cannot estimate a release date.
- Sagent has carboplatin 5 mL, 15 mL, 45 mL, and 60 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1005>

### Fludarabine Injection

**March 24, 2017**

#### Reason for the Shortage

- Actavis has fludarabine available.
- Fresenius Kabi has fludarabine on shortage due to increased demand.
- Pfizer has fludarabine on shortage due to increased demand.
- Sagent has fludarabine 25 mg/mL 2 mL vials on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Fresenius Kabi has fludarabine 25 mg/mL 2 mL vials on back order and the company estimates a release date of early-April 2017.
- Pfizer has fludarabine lyophilized powder 50 mg vials on back order and the company estimates a release date of late-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=648>

### Hydralazine Injection

**March 24, 2017**

#### Reason for the Shortage

- Akorn did not provide a reason for the hydralazine injection on shortage.
- American Regent has hydralazine injection on shortage due to manufacturing delays.
- Fresenius Kabi has hydralazine injection available.
- X-Gen launched hydralazine injection in September 2015.

#### Estimated Resupply Dates

- American Regent has hydralazine 20 mg/mL 1 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1129>

### Ketorolac Tromethamine Injection

**March 24, 2017**

#### Reason for the Shortage

- BD Rx has ketorolac injection available. BD RX is now part of Fresenius Kabi.

- Fresenius Kabi has ketorolac injection available.
- Pfizer has ketorolac injection available.
- Sagent states the reason for the shortage is manufacturing delay.
- West-Ward is not actively marketing ketorolac injection.
- Ben Venue closed its plant in Bedford, Ohio in July 2014.
- FDA imposed an import ban in mid-2013 on several Wockhardt products including ketorolac.
- Sprix Nasal Spray is not affected by this shortage.

Estimated Resupply Dates

- Sagent has ketorolac 15 mg/mL 1 mL vials, 30 mg/mL 1 mL vials, and 30 mg/mL 2 mL vials for intramuscular injection on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=593>

### Methylene Blue Injection

**March 24, 2017**

Reason for the Shortage

- Akorn has methylene blue on shortage due to manufacturing delays.
- American Regent has recently launched an FDA approved presentation, ProveyBlue and product is available.

Estimated Resupply Dates

- Akorn has temporarily suspended manufacturing of methylene blue and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=27>

### Ofloxacin Ophthalmic Solution

**March 24, 2017**

Reason for the Shortage

- Allergan has Ocuflax ophthalmic solution available.
- Akorn did not provide a reason for the shortage.
- Rising has ofloxacin ophthalmic solution available.
- Valeant did not provide a reason for the shortage.

Estimated Resupply Dates

- Akorn has ofloxacin ophthalmic solution in 5 mL bottles on back order and the company estimates a release date of mid-April 2017. The 10 mL bottles are on allocation.
- Valeant has temporarily discontinued ofloxacin ophthalmic solution in 5 mL and 10 mL bottles and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1235>

### Oxacillin Sodium Injection

**March 24, 2017**

Reason for the Shortage

- Auromedics did not provide a reason for the shortage.
- Baxter has oxacillin on shortage due to a raw material supply disruption.
- Sagent has oxacillin injection on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- AuroMedics has oxacillin 2 gram vials on intermittent back order and the company is releasing supplies as they become available.
- Baxter has 1 gram/50 mL frozen premixed bags available in limited supply.
- Sagent has oxacillin 1 gram vials on back order and the company cannot estimate a release date. The 2 gram and 10 gram vials are on back order and the company estimates a release date of May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1121>

#### Rocuronium Injection

**March 24, 2017**

#### Reason for the Shortage

- Fresenius Kabi has rocuronium on shortage due to delay of raw materials.
- Pfizer has rocuronium on shortage due to manufacturing delays.
- Sagent has rocuronium on shortage due to increased demand.
- X-Gen has rocuronium on shortage due to increased demand.

#### Estimated Resupply Dates

- Fresenius Kabi has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of 2nd quarter 2017.
- Pfizer has rocuronium 10 mg/mL 5 mL and 10 mL vials available in limited supply.
- Sagent has rocuronium 10 mg/mL 5 mL and 10 mL vials on back order and the company estimates a release date of April 2017 for the 5 mL vials and cannot estimate a release date for the 10 mL vials.
- X-Gen has rocuronium on 10 mg/mL 5 mL vials on back order and the company estimates a release date of March 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=434>

#### Yellow Fever Vaccine Injection

**March 27, 2017**

#### Reason for the Shortage

- Sanofi Pasteur could not provide a reason for the shortage of YF-Vax.
- There are no other suppliers of yellow fever vaccine.
- Additional information is available

#### Estimated Resupply Dates

- Sanofi Pasteur has YF-Vax multi-dose vials and single dose vials available in limited supply. Customers can call Sanofi Pasteur to order product for patients traveling in the next 30 days.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=383>

#### Tetanus and Diphtheria Toxoids Adsorbed

**March 27, 2017**

#### Reason for the Shortage

- Grifols has tetanus and diphtheria toxoids adsorbed (Td) available.
- Sanofi Pasteur has Tenivac on shortage due to manufacturing delays.
- Adult tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccines are not affected by this shortage.



- Pediatric diphtheria and tetanus toxoids adsorbed (DT) and diphtheria and tetanus toxoids and acellular pertussis vaccines (DTaP) are not affected by this shortage.

Estimated Resupply Dates

- Sanofi Pasteur has Tenivac on back order and the company estimates a release date in June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1260>

### Methylphenidate Hydrochloride Chewable Tablets

**March 27, 2017**

Reason for the Shortage

- Shionogi Pharma has Methylin chewable tablets on shortage due to manufacturing issues.
- Gavis launched methylphenidate chewable tablets in April 2015.

Estimated Resupply Dates

- Shionogi Pharma has all Methylin chewable tablets on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1163>

### Lidocaine Topical 4% Solution

**March 27, 2017**

Reason for the Shortage

- Amphastar did not provide a reason for the shortage.
- Teligent did not provide a reason for the shortage.
- West-Ward did not provide a reason for the shortage.

Estimated Resupply Dates

- Teligent has lidocaine topical 4% solution in 50 mL bottles on allocation.
- West-Ward has lidocaine topical 4% solution in 50 mL bottles on back order and the company estimates a release date in early-April 2017.
- Amphastar has Laryng-O-Jet syringes available in limited quantities and the company is releasing product regularly. The company estimates the product will be readily available in mid- to late-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1128>

### Olanzapine Injection

**March 28, 2017**

Reason for the Shortage

- Sandoz did not provide a reason for the shortage of olanzapine intramuscular injection.

Estimated Resupply Dates

- Sandoz has olanzapine 10 mg vials on back order and the company estimates a release date of mid-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1093>

### Ceftazidime Injection

March 30, 2017

#### Reason for the Shortage

- IGI Laboratories changed its name to Teligent in late-October 2015.
- Covis divested Fortaz injection to IGI Laboratories in October 2015.
- Pfizer had Tazicef on shortage due to manufacturing delays.
- Sagent has ceftazidime injection on shortage due to manufacturing delays.
- Sandoz discontinued ceftazidime 1 gram and 2 gram vials in 2015.
- BBraun had ceftazidime on allocation due to increased demand.
- WG Critical Care has ceftazidime on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Sagent has ceftazidime 1 gram, 2 gram, and 6 gram vials on allocation.
- Teligent has Fortaz 500 mg, 1 gram, 2 gram, and 6 gram vials on back order and the company estimates a release date of mid-April 2017 for the 500 mg vials, early-May 2017 for the 1 gram vials, and the company cannot estimate a release date for the 2 gram and 6 gram vials.
- WG Critical Care has ceftazidime 1 gram, 2 gram, and 6 gram vials on back order and the company estimates a release date of June 2017 for the 2 gram vials and July 2017 for the 1 gram and 6 gram vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=869>

### Cefoxitin Sodium Injection

March 30, 2017

#### Reason for the Shortage

- Fresenius Kabi and West-Ward did not provide a reason for the shortage.
- Sagent has cefoxitin on shortage due to manufacturing delays.
- BBraun has cefoxitin on allocation due to increased demand.

#### Estimated Resupply Dates

- BBraun has cefoxitin 2 gram premixes on back order and the company cannot estimate release date. Check wholesalers for inventory.
- Fresenius Kabi has cefoxitin 1 gram vials on back order and the company estimates a release date of early-June 2017.
- Sagent has cefoxitin 10 gram vials on back order and the company estimates a release date of April 2017.
- West-Ward has cefoxitin 1 gram, 2 gram, and 10 gram vials on back order and the company estimates a release date of April or May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1256>

### Acetazolamide Injection

March 31, 2017

#### Reason for the Shortage

- West-Ward has acetazolamide injection available.
- Sagent has acetazolamide injection on shortage due to manufacturing delays.
- X-Gen has acetazolamide injection available.

#### Estimated Resupply Dates

- Sagent has acetazolamide 500 mg vials on back order and the company estimates a release date of April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=463>

### Sodium Phosphate Injection

April 3, 2017

#### Reason for the Shortage

- American Regent has sodium phosphate injection on shortage due to manufacturing delay.
- Fresenius Kabi states the reason for the shortage was increased demand. They are no longer importing Glycophos.
- Pfizer had sodium phosphate injection on shortage due to manufacturing delay.

#### Estimated Resupply Dates

- American Regent has sodium phosphate 3 mmol/mL 5 mL, 15 mL, and 50 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=770>

### Piperacillin Tazobactam Injection

April 3, 2017

#### Reason for the Shortage

- Apotex has piperacillin/tazobactam on shortage due to regulatory delays.
- AuroMedics and Sandoz could not provide a reason for the shortage.
- Baxter has Zosyn frozen premixes on allocation due to increased demand.
- Fresenius Kabi has piperacillin/tazobactam on shortage due to increased demand.
- Mylan Institutional launched piperacillin/tazobactam 3.375 gram and 4.5 gram vials in early-June 2016.
- Pfizer has Zosyn on shortage due to manufacturing delays.
- Sagent has piperacillin/tazobactam on shortage due to increased demand.
- Sandoz has piperacillin/tazobactam available for contracted customers.
- WG Critical Care states the reason for the shortage is increased demand.
- FDA in conjunction with SteriMax is allowing temporary importation of piperacillin/tazobactam 3.375 gram, 4.5 gram, and 40.5 gram vials from Canada. This will be distributed through X-Gen Pharmaceuticals. The product codes on these items will not be recognized by U.S. systems so institutions will need to implement alternative plans to assure the dose is being given correctly.
- X-Gen recently launched piperacillin/tazobactam injection.

#### Estimated Resupply Dates

- Apotex has piperacillin/tazobactam 2.25 gram, 3.375 gram, 4.5 gram, and 40.5 gram vials on back order and the company estimates a release date of late-June 2017.
- AuroMedics has piperacillin/tazobactam on intermittent back order and the company is releasing product as it becomes available. Check wholesalers for inventory.
- Baxter has all frozen piperacillin/tazobactam presentations available in limited supply.
- Fresenius Kabi has piperacillin/tazobactam 2.25 gram vials on intermittent back order and the company is releasing product as it becomes available. The 4.5 gram and 40.5 gram vials are on back order and the company estimates a release date of mid-May 2017 for the 4.5 gram vials and early-May 2017 for the 40.5 gram vials.
- Pfizer has piperacillin/tazobactam 3.375 gram, 4.5 gram, and 40.5 gram vials available in limited supply. The 2.25 gram vials, 2.25 gram ADD-Vantage vials, and 4.5 gram ADD-Vantage vials are available in limited supply. The 3.375 gram ADD-Vantage vials are on back order and the company estimates a release date of late-May 2017.
- Pfizer has Zosyn 2.25 gram vials, 3.375 gram vials, 4.5 gram vials, and 40.5 gram vials on back order and the company estimates a release date of January 2018.

- Sagent has piperacillin/tazobactam 3.375 gram and 4.5 gram vials on allocation.
- Sandoz has piperacillin/tazobactam 2.25 gram (NDC 00781-3344-95), 3.375 gram (NDC 00781-3350-95), and 4.5 gram (NDC 00781-3367-95) vials on back order and the company cannot estimate a release date.
- WG Critical Care has piperacillin/tazobactam 2.25 gram, 3.375 gram, 4.5 gram, and 40.5 gram vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1075>

### Penicillin G Procaine Injection

**April 3, 2017**

#### Reason for the Shortage

- Pfizer has penicillin G procaine on shortage due to manufacturing delays.
- Pfizer is the sole supplier of penicillin G procaine.

#### Estimated Resupply Dates

- Pfizer has penicillin G procaine 600,000 unit/mL 1 mL and 2 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1238>

### Penicillin G Benzathine/Penicillin G Procaine

**April 3, 2017**

#### Reason for the Shortage

- Pfizer has Bicillin C-R and Bicillin C-R 900/300 on shortage due to manufacturing delays

#### Estimated Resupply Dates

- Pfizer has Bicillin C-R 1,200,000 units/2 mL prefilled syringes and 1,200,000 units/2 mL pediatric prefilled syringes on allocation.
- Pfizer has Bicillin C-R 900/300 2 mL pediatric prefilled syringes on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1249>

### Penicillin G Benzathine

**April 3, 2017**

#### Reason for the Shortage

- Pfizer states the shortage is due to a delay in the manufacturing process.

#### Estimated Resupply Dates

- Pfizer has Bicillin L-A 600,000 unit/ 1 mL syringes, 1,200,000 unit/ 2 mL syringes, and 2,400,000 unit/ 4 mL syringes on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1232>

### Methylprednisolone Acetate Injection

**April 3, 2017**

#### Reason for the Shortage

- Sandoz could not provide a reason for the shortage.

- Pfizer had Depo-Medrol injection on a short-term shortage due to increased demand of Solu-Medrol.
- Teva is not actively marketing methylprednisolone acetate.

Estimated Resupply Dates

- Sandoz has methylprednisolone acetate injection temporarily unavailable and the company cannot estimate a release date

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=923>

### Labetalol Injection

**April 3, 2017**

Reason for the Shortage

- Akorn has labetalol injection on shortage due to increased demand.
- Pfizer has labetalol injection on shortage due to manufacturing delays.
- West-Ward has labetalol injection available.

Estimated Resupply Dates

- Akorn has labetalol 5 mg/mL 20 mL and 40 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Pfizer has labetalol 5 mg/mL 20 mL and 40 mL vials on back order and the company estimates a release date of early-April 2017. The 5 mg/mL 4 mL syringes are on back order and the company estimates a release date of early-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=397>

### Estradiol Valerate Injection

**April 3, 2017**

Reason for the Shortage

- Par states the reason for the shortage is manufacturing delay.
- Perrigo states the reason for the shortage is manufacturing issues.

Estimated Resupply Dates

- Par Sterile Products has Delestrogen 10 mg/mL 5 ml vials, 20 mg/mL 5 mL vials, and 40 mg/mL 5 mL vials on back order and the company estimates a release date of 2nd quarter 2017.
- Perrigo has estradiol valerate 20 mg/mL 5 mL vials on intermittent back order and the company is releasing product as it becomes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1186>

### Disopyramide Phosphate Controlled-release Capsules

**April 3, 2017**

Reason for the Shortage

- Pfizer has disopyramide controlled-release capsules on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer has Norpace CR 100 mg capsules in 100 count and 150 mg capsules in 100 count available but with an expiration date of June 2017. The 100 mg capsules in 500 count and 150 mg capsules in 500 count are on back order and the company estimates a release date of March 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1139>

### Dihydroergotamine Mesylate Injection

**April 3, 2017**

#### Reason for the Shortage

- Perrigo and Valeant did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Perrigo has dihydroergotamine 1 mg/mL 1 mL ampules in 5 count and 10 count on intermittent back order with regular releases.
- Valeant has D.H.E. 45 1 mg/mL 1 mL ampules on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1050>

### Dexrazoxane Injection

**April 3, 2017**

#### Reason for the Shortage

- Biocodex USA acquired Totect from Apricus Pharmaceuticals in April 2013.
- Mylan Institutional has dexrazoxane available.
- West-Ward is not actively marketing dexrazoxane injection at this time.

#### Estimated Resupply Dates

- Biocodex USA has not yet started manufacturing Totect and the company cannot estimate when product will be available.
- Pfizer has Zinecard 500 mg vials on back order and the company estimates a release date of 4th quarter 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=415>

### Cefotetan Disodium Injection

**April 3, 2017**

#### Reason for the Shortage

- BBraun has cefotetan available.
- Fresenius Kabi states the reason for the shortage was manufacturing delay.
- Teligent has Cefotan available.

#### Estimated Resupply Dates

- All marketed presentations are available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1097>

### Alcohol Dehydrated Injection (Ethanol)

**April 4, 2017**

#### Reason for the Shortage

- Akorn states the back order was due to manufacturing delays.

#### Estimated Resupply Dates

- American Regent has dehydrated alcohol 1 mL ampules on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=778>

### Ceftriaxone Sodium Injection

**April 4, 2017**

#### Reason for the Shortage

- Fresenius Kabi states the reason for the shortage is increased demand.
- Pfizer states the reason for the shortage was manufacturing delay.
- Sagent states the reason for the shortage is manufacturing delay.
- Sandoz cannot provide a reason for the shortage.
- West-Ward states the reason for the shortage is manufacturing delay.
- WG Critical Care states the reason for the shortage is increased demand.

#### Estimated Resupply Dates

- Apotex has ceftriaxone 2 gram vials on back order and the company estimates a release date of late-June 2017.
- Fresenius Kabi has ceftriaxone 2 gram vials on back order and the company estimates a released date of 2nd quarter 2017. The 500 mg vials are on back order and the company cannot estimate a release date.
- Pfizer has ceftriaxone 2 gram ADD-Vantage on back order and the company estimates a release date in late-April 2017. All other ceftriaxone presentations are available in limited supply.
- Lupin has all ceftriaxone presentations on allocation.
- Sagent has ceftriaxone 1 gram vials on allocation.
- Sandoz has ceftriaxone 500 mg and 10 gram vials on back order and the company estimates a release date of late-April 2017.
- WG Critical Care has ceftriaxone 10 gram vials on back order and the company estimates a release date of early-May 2017.
- West-Ward has ceftriaxone 250 mg vials on back order and the company cannot estimate a release date. The 1 gram vials are on allocation.
- Wockhardt has ceftriaxone 250 mg, 500 mg, 1 gram, and 2 gram vials on back order and the company estimates a release date of late-April to early-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1101>

### Dextrose 5% Injection Large Volume Bags

**April 4, 2017**

#### Reason for the Shortage

- Pfizer states the shortage is due to increased demand and manufacturing delays.
- Baxter did not provide a reason for the shortage.
- 5% dextrose 1,000-mL bags are not affected at this time.

#### Estimated Resupply Dates

- Baxter has 5% dextrose 250 mL and 500 mL PVC/DEHP-free bags on back order and the company cannot estimate a release date.
- Pfizer has 5% dextrose 250 mL PVC/DEHP-free bags on back order and the company estimates a release date in early-April 2017. Pfizer has 5% dextrose 250 mL (2 port) bags on back order and the company estimates a release date in mid-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1081>

## Dopamine Hydrochloride Injection

April 4, 2017

### Reason for the Shortage

- American Regent has dopamine on shortage due to manufacturing delays.
- Baxter could not provide a reason for the shortage.
- Pfizer states the shortage is due to manufacturing delays.

### Estimated Resupply Dates

- American Regent has all dopamine presentations on back order and the company cannot estimate a release date.
- Pfizer has dopamine 40 mg/mL 10 mL vials on back order and the company estimates a release date of 3rd quarter 2017. The dopamine 400 mg/250 mL premixed bags are on back order and the company estimates a release date of late-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1243>

## Hepatitis A Virus Vaccine Inactivated

April 4, 2017

### Reason for the Shortage

- Merck did not provide a reason for the Vaqta shortage.
- GlaxoSmithKline did not provide a reason for the Havrix shortage.

### Estimated Resupply Dates

- Merck has Vaqta pediatric/adolescent formulation 25U/0.5 mL prefilled syringes in 10 count on back order and the company estimates a release date in 3rd quarter 2017.
- Merck has Vaqta adult formulation 50U/1 mL vials in 1 count on back order and the company estimates product will not be available in 2017. Merck has Vaqta adult formulation 50U/1 mL prefilled syringes on back order and the company estimates a release date in mid-April 2017. Vaqta 50U/1 mL vials in 10 count are on back order and the company estimates a release date in 2nd quarter 2017.
- GlaxoSmithKline Vaccines has Havrix adult syringes and Havrix adult single dose vials in 10 count on back order and the company estimates a release date in May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=180>

## Lorazepam injectable presentations

April 4, 2017

### Reason for the Shortage

- Bedford discontinued lorazepam injection in May, 2011.
- West-Ward has product on shortage due to manufacturing delays.
- Pfizer has product on shortage due to increased demand and manufacturing delays.
- Akorn has not provided a reason for the shortage.
- Amphastar has product available.

### Estimated Resupply Dates

- Akorn has lorazepam 2 mg/mL 1 mL vials on intermittent back order and is releasing product as it becomes available.
- Pfizer has lorazepam 2 mg/mL 1 mL vials and 1 mL Carpuject syringes available in limited supply.
- West-Ward has lorazepam 2 mg/mL 1 mL vials and 4 mg/mL 10 mL vials on a weekly allocation.
- West-Ward has Ativan 2 mg/mL 1 mL vials on back order and the company estimates a release date of mid-April to mid-May 2017. The 4 mg/mL 10 mL vials are on a weekly allocation.



<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=747>

### **Methylphenidate Transdermal**

**April 4, 2017**

#### Reason for the Shortage

- Noven has Daytrana patches on shortage due to packaging problems.

#### Estimated Resupply Dates

- Noven has all Daytrana presentations on intermittent back order and the company is releasing supplies as they become available. Noven estimates a full recovery in June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1216>

### **Octreotide Injection**

**April 4, 2017**

#### Reason for the Shortage

- Fresenius Kabi did not provide a reason for the shortage.
- Mylan Institutional has octreotide available.
- Sagent has octreotide on shortage due to manufacturing delays.
- Sun Pharma refuses to provide availability information at this time.
- Teva has octreotide available.
- Novartis has Sandostatin available.

#### Estimated Resupply Dates

- Fresenius Kabi has octreotide 50 mcg/mL 1 mL vials on back order and the company estimates a release date of 1st quarter 2018.
- Sagent has octreotide 100 mcg/mL 1 mL vials, 200 mcg/mL 5 mL vials, and 500 mcg/mL 1 mL on back order and the company estimates a release date of April 2017 for the 100 mcg/mL 1 mL vials and 200 mcg/mL 5 mL vials, and June 2017 for the 500 mcg/mL 1 mL vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=803>

### **Potassium Chloride Injection**

**April 4, 2017**

#### Reason for the Shortage

- Baxter has a consistent supply of potassium chloride injection.
- Fresenius Kabi has some potassium chloride injection available.
- Pfizer has potassium chloride injection on shortage due to increase demand and manufacturing delays.

#### Estimated Resupply Dates

- Fresenius Kabi has potassium chloride 20 mEq/10 mL on back order and the company estimates a release date in late-April 2017.
- Pfizer has potassium chloride 20 mEq/1000 mL in 0.9% sodium chloride on back order and the company estimates a release date in mid-April 2017. Pfizer has potassium chloride 2 mEq/mL 250 mL vials and 10 mEq/500 mL in 5% dextrose and 0.225% sodium chloride on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=696>

## Promethazine Injection

April 4, 2017

### Reason for the Shortage

- Teva is not marketing promethazine injection at this time.
- West-Ward states the shortage is due to manufacturing delays.
- Hospira discontinued promethazine in 2016.
- X-Gen has promethazine available.

### Estimated Resupply Dates

- West-Ward has promethazine 25 mg/mL 1 mL vials and 50 mg/mL 1 mL vials on back order and the company cannot estimate a release date. The 25 mg/mL 1 mL ampules are on back order and the company estimates a release date of mid-April to early-May 2017. The 50 mg/mL 1 mL ampules are on a weekly allocation.
- West-Ward has Phenergan 25 mg/mL 1 mL vials and 50 mg/mL 1 mL vials on back order and the company cannot estimate a release date. Phenergan 25 mg/mL 1 mL ampules are on back order and the company estimates a release date of mid-April to early-May 2017.
- X-Gen has promethazine 25 mg/mL 1 mL ampules on back order and the company estimates a release date of late-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=654>

## Rabies Vaccine

April 4, 2017

### Reason for the Shortage

- GlaxoSmithKline Vaccines could not provide a reason for the RabAvert shortage.

### Estimated Resupply Dates

- GlaxoSmithKline Vaccines has RabAvert on back order and the company estimates a release date in April 2017. Emergency stock is available if a patient has been exposed.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=959>

## Sodium Chloride 0.9% Injection Bags

April 4, 2017

### Reason for the Shortage

- Baxter discontinued 0.9% sodium chloride 250 mL and 500 mL AVIVA bags. The other presentations are available.
- BBraun has 0.9% sodium chloride on allocation.
- Pfizer cited increased demand as the reason for the shortage.
- Fresenius Kabi is no longer importing product.
- Baxter has received FDA approval for 0.9% sodium chloride in Viaflo containers manufactured in an FDA-approved facility in Spain.

### Estimated Resupply Dates

- BBraun has 0.9% sodium chloride in 250 mL, 500 mL, and 1000 mL PVC/DEHP-free bags on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=993>

### Tetracaine Hydrochloride Ophthalmic Drops

April 4, 2017

#### Reason for the Shortage

- Valeant and OCuSOFT did not provide a reason for the shortage.

#### Estimated Resupply Dates

- OCuSOFT has Tetravisc 0.5% 5 mL bottles and 0.6 mL unit-dose containers in 12 count on back order and the company cannot estimate a release date.
- OCuSOFT has Tetravisc Forte 0.5% 5 mL bottles and 0.6 mL unit-dose containers in 12 count on back order and the company cannot estimate a release date.
- Valeant has tetracaine 0.5% 15 mL bottles on intermittent back order and the company is releasing product as it becomes available.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1242>

### Thiotepa for Injection

April 4, 2017

#### Reason for the Shortage

- West-Ward launched thiotepa in August 2015.
- FDA was allowing temporary importation of Tepadina (thiotepa), from Adienne SA in Italy. There may still be product available at some healthcare centers but importation stopped in December 2015.

#### Estimated Resupply Dates

- West-Ward has thiotepa available with an expiration date of < February 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=589>

### Fluoxymesterone Tablets

April 5, 2017

#### Reason for the Shortage

- Upsher-Smith has discontinued Androxy tablets in October 2014.
- Upsher-Smith was the sole manufacturer of fluoxymesterone.

#### Estimated Resupply Dates

- Upsher-Smith discontinued Androxy tablets. There are no alternative suppliers of fluoxymesterone tablets.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1140>

### Famotidine Injection

April 5, 2017

#### Reason for the Shortage

- Ben Venue stopped production in its plant in Bedford, Ohio and closed in July 2014.
- West-Ward states the shortage was due to manufacturing delays.
- Oral famotidine products are not affected by this shortage.
- Pfizer launched famotidine injections in March, 2012.
- Mylan Institutional acquired famotidine injections from Pfizer on December 6, 2013.
- Baxter has famotidine premixed bags available.

- Fresenius Kabi did not provide a reason for the shortage.

Estimated Resupply Dates

- Mylan Institutional has temporarily discontinued famotidine 10 mg/mL 2 mL vials and has famotidine 10 mg/mL 4 mL and 20 mL vials on back order. The company estimates a release date of late-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=810>

### Doxorubicin Injection

**April 5, 2017**

Reason for the Shortage

- West-Ward has Adriamycin available.
- Teva has doxorubicin solution for injection available.
- Fresenius Kabi has doxorubicin solution for injection available.
- Caraco has discontinued doxorubicin solution for injection 25 mL and 100 mL vials.
- Pfizer has doxorubicin solution for injection available.
- Sagent has doxorubicin solution for injection on back order due to manufacturing delays.
- Mylan Institutional has doxorubicin lyophilized powder for injection available.
- Actavis has doxorubicin injection available.
- FDA is allowing temporary importation of doxorubicin lyophilized powder for injection 50 mg vials. These vials were manufactured for Hospira UK Limited. The labeling as well as bar coding for the imported product is different from the US version. FDA has the Dear Healthcare Professional Letter linked on their website. The letter includes a link to both the US and United Kingdom package inserts to help explain the differences in labeling and packaging.

Estimated Resupply Dates

- Sagent has doxorubicin 2 mg/mL 5 mL, 25 mL, and 100 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=464>

### Lidocaine Injection

**April 6, 2017**

Reason for the Shortage

- Amphastar had lidocaine 2% emergency syringes on shortage due to increase demand for the product.
- AuroMedics introduced lidocaine injection in February 2014.
- Fresenius Kabi had generic lidocaine presentations on shortage due to a supply interruption of raw ingredients.
- Pfizer has lidocaine presentations on shortage due to manufacturing delays.

Estimated Resupply Dates

- AuroMedics has 1% lidocaine 2 mL and 5 mL vials on intermittent back order and the company is releasing product as it becomes available. AuroMedics has 2% lidocaine 2 mL and 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has 1% Xylocaine-MPF 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Pfizer has 2% lidocaine 5 mL vials and 5 mL LifeShield syringes available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=859>

### Levetiracetam Injection

April 6, 2017

#### Reason for the Shortage

- American Regent has product available.
- AuroMedics did not provide a reason for the shortage.
- Caraco will not provide availability information on levetiracetam.
- Fresenius Kabi had levetiracetam injection on shortage due to manufacturing delays.
- Mylan has product available.
- Pfizer has product available.
- Sagent has levetiracetam injection on shortage due to manufacturing delays.
- UCB has product available.
- West-Ward has product available.
- X-Gen has product available.

#### Estimated Resupply Dates

- AuroMedics has levetiracetam 100 mg/mL 5 mL vials on intermittent back order and the company is releasing product as it becomes available.
- Sagent has levetiracetam 100 mg/mL 5 mL vials on back order and the company estimates a release date of July 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1183>

### Leucovorin Calcium Injection

April 6, 2017

#### Reason for the Shortage

- Fresenius Kabi has leucovorin on shortage due to increase demand.
- Teva had leucovorin on allocation due to increased demand.
- West-Ward has leucovorin available.
- Sagent has leucovorin on shortage due to manufacturing delay.

#### Estimated Resupply Dates

- Fresenius Kabi has leucovorin 500 mg vials on back order and the company estimates a release date of early- to mid-May 2017.
- Sagent has leucovorin 50 mg, 100 mg, and 350 mg vials on allocation.
- West-Ward has leucovorin 350 mg vials on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=488>

### Cefepime Injection

April 6, 2017

#### Reason for the Shortage

- Apotex could not provide a reason for the shortage.
- Baxter had cefepime on shortage due to increased demand.
- BBraun has cefepime on shortage due to increased demand.
- Fresenius Kabi has cefepime injection on shortage due to manufacturing delays.
- Pfizer has Maxipime on shortage due to manufacturing delays.
- Sagent has cefepime injection on shortage due to manufacturing delays.
- Sandoz discontinued cefepime injection in early-2016.

- WG Critical Care had cefepime injection on shortage due to increased demand

#### Estimated Resupply Dates

- Apotex has cefepime 1 gram vials in 1 count on back order and the company cannot estimate a release date.
- BBraun has cefepime 1 gram premixed bags on back order and the company estimates a release date of late-April 2017.
- Fresenius Kabi has cefepime 1 gram vials on back order and the company estimates a release date of early-June 2017.
- Pfizer has Maxipime 2 gram ADD-Vantage vials and 2 gram vials on allocation. The 1 gram vials are on back order and the company estimates a release date of March 2017. The 1 gram ADD-Vantage vials are on back order and the company estimates a release date of July 2017.
- Sagent has cefepime 1 gram vials on back order and the company estimates a release date of June 2017. The 2 gram vials are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1176>

### Vecuronium Bromide Injection

**April 7, 2017**

#### Reason for the Shortage

- Pfizer has vecuronium on shortage due to manufacturing delays.
- Teva is not actively marketing vecuronium.
- Pfizer sold vecuronium injection to Mylan Institutional in December 2013.
- Ben Venue has stopped production in its plant in Bedford, Ohio and closed in 2014.
- Caraco will not provide availability information at this time.
- Sagent is not marketing vecuronium 10 mg and 20 mg vials.

#### Estimated Resupply Dates

- Pfizer has vecuronium 10 mg and 20 m vials available in limited supply.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=490>

### Norepinephrine Bitartrate Injection

**April 7, 2017**

#### Reason for the Shortage

- Claris has norepinephrine injection available.
- Pfizer has Levophed on shortage due to manufacturing delays.
- Teva has norepinephrine injection available.

#### Estimated Resupply Dates

- Pfizer has Levophed 1 mg/mL 4 mL vials and ampules on back order and the company estimates a release date of early-April 2017 for the vials and April 2017 for the ampules.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1262>

### Indigo Carmine Injection

**April 7, 2017**

#### Reason for the Shortage

- American Regent has indigo carmine on back order due to manufacturing delays.

- Akorn has discontinued production of indigo carmine due to shortage of raw material.

#### Estimated Resupply Dates

- American Regent has indigo carmine 8 mg/mL 5 mL ampules on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=861>

### Cefuroxime Sodium Injection

**April 7, 2017**

#### Reason for the Shortage

- Teligent has Zinacef on shortage due to increased demand.
- West-Ward did not provide a reason for the cefuroxime injection shortage.

#### Estimated Resupply Dates

- Sagent has cefuroxime 7.5 gram vials on back order and the company cannot estimate a release date.
- Teligent has Zinacef 1.5 gram vials on back order and the company estimates a release date of May 2017. Zinacef 750 mg and 1.5 gram ADD-Vantage vials are on back order and the company estimates a release date of May 2017. The 750 mg and 7.5 gram vials are on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=990>

### Bupivacaine with epinephrine Injection

**April 7, 2017**

#### Reason for the Shortage

- Fresenius Kabi has bupivacaine and epinephrine on shortage due to increased demand and manufacturing delays.
- Pfizer has bupivacaine with epinephrine on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL vials and 0.5% Sensorcaine-MPF with epinephrine 10 mL vials on back order and the company estimates a release date of mid-April 2017. The 0.25% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of early-April 2017. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of early-April 2017. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials sterile packs are on back order and the company estimates a release date of early-May 2017. The 0.5% Sensorcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-April 2017.
- Pfizer has 0.25% bupivacaine with epinephrine 30 mL preservative-free vials and 50 mL vials on allocation. The 0.5% bupivacaine with epinephrine 10 mL and 30 mL preservative-free vials are on back order and the company estimates a release date of late-April 2017 for the 10 mL vials and early-June 2017 for the 30 mL vials. The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of mid-June 2017.
- Pfizer has 0.25% Marcaine with epinephrine 10 mL preservative-free vials on allocation. The 0.25% Marcaine with epinephrine 50 mL vials are on back order and the company estimates a release date of early-April 2017. The 0.5% Marcaine with epinephrine 10 mL and 30 mL preservative-free vials are on allocation.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=937>

## Ampicillin Sulbactam

April 7, 2017

### Reason for the Shortage

- Mylan Institutional discontinued ampicillin sulbactam 1.5 gram and 3 gram vials.
- Pfizer has discontinued generic ampicillin sulbactam.
- Sandoz cannot provide a reason for the shortage.
- Sagent has ampicillin sulbactam vials on allocation due to manufacturing delays.
- WG Critical Care states the shortage was due to increased demand.

### Estimated Resupply Dates

- AuroMedics has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on intermittent back order and the company is releasing product as it becomes available.
- Fresenius Kabi has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials on back order and the company cannot estimate a release date.
- Mylan Institutional has ampicillin sulbactam 15 gram bulk vials on back order and the company estimates a release date of late-April 2017.
- Sagent has ampicillin sulbactam 3 gram vials on allocation.
- Sandoz has ampicillin sulbactam 1.5 gram, 3 gram, and 15 gram vials temporarily unavailable and the company cannot estimate a release date.
- West-Ward has ampicillin sulbactam 1.5 gram and 3 gram vials on a weekly allocation. The 15 gram vials are on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=805>

## Lidocaine Hydrochloride Oral Topical Solution (Viscous) 2%

April 10, 2017

### Reason for the Shortage

- Akorn has viscous lidocaine 100 mL bottles on shortage due to increased demand.
- West-Ward did not provide a reason for the viscous lidocaine shortage.

### Estimated Resupply Dates

- Akorn has viscous lidocaine 100 mL bottles on back order and product is being allocated upon release.
- West-Ward has viscous lidocaine 100 mL bottles on back order and the company estimates a release date in mid-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1171>

## Vancomycin Hydrochloride Injection

April 11, 2017

### Reason for the Shortage

- Pfizer has vancomycin bulk vials on back order due to manufacturing delays. All other presentations are available.
- Fresenius Kabi has vancomycin injection on shortage due to increased demand.
- Mylan Institutional has vancomycin injection available.
- Baxter could not provide a reason for the shortage of vancomycin 500 mg/100 mL frozen premixed bags. All other presentations are available.
- Sagent has vancomycin injection on shortage due to manufacturing delays.

### Estimated Resupply Dates

- Fresenius Kabi has vancomycin 10 gram vials on intermittent back order with regular releases.



- Sagent has vancomycin 10 gram vials on back order and the company estimates a release date of April 2017.
- Baxter has vancomycin 500 mg/100 mL frozen premixed bags in 6 count on back order and the company cannot estimate a release date. Vancomycin 500 mg/100 mL frozen premixed bags in 12 count are available in limited quantities.
- Pfizer has vancomycin lyophilized powder 5 gram vials on back order and the company cannot estimate a release date. The vancomycin lyophilized powder 10 gram vials are on back order and the company estimates a release date of mid-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=132>

### Sodium Nitroprusside Injection

**April 11, 2017**

#### Reason for the Shortage

- Valeant has Nitropress available but short-dated.
- Sagent launched sodium nitroprusside 25 mg/mL 2 mL vials in late 2016. They have product available.
- Exela launched Nipride RTU 0.5 mg/mL 100 mL vials in March 2017.

#### Estimated Resupply Dates

- Valeant has Nitropress 25 mg/mL 2 mL vials available with an expiration date of February 2018.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1223>

### Scopolamine Transdermal System

**April 11, 2017**

#### Reason for the Shortage

- Baxter has Transderm Scop in 10 count and 24 count available.
- Sandoz has Transderm Scop on shortage due to increased demand. Sandoz changed their NDC number in late 2016.

#### Estimated Resupply Dates

- Sandoz has Transderm Scop in 4 count on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=837>

### Indomethacin Capsules

**April 11, 2017**

#### Reason for the Shortage

- Glenmark had indomethacin 25 mg 100 count on shortage due to manufacturing delays.
- Heritage did not provide a reason for the shortage.
- Sandoz discontinued indomethacin in mid-2016.
- Teva did not provide a reason for the shortage.

#### Estimated Resupply Dates

- Glenmark has indomethacin 25 mg capsules in 100 count on back order and the company estimates a shipment date of mid-to late-May 2017.
- Heritage has indomethacin 50 mg capsules in 100 count and 500 count on back order and the company cannot estimate a release date. Heritage has short-dated indomethacin 25 mg capsules in 100 count and 1000 count available.

- Teva has all indomethacin presentations temporarily unavailable and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1236>

### Haloperidol Lactate Injection

**April 11, 2017**

#### Reason for the Shortage

- Mylan Institutional has haloperidol lactate injection available.
- Patriot Pharmaceuticals has haloperidol lactate available.
- Sagent has haloperidol lactate on shortage due to manufacturing delays.
- Teva is not currently marketing haloperidol lactate.
- West-Ward is not actively marketing haloperidol lactate at this time.
- Janssen has Haldol injection available.

#### Estimated Resupply Dates

- Sagent has haloperidol lactate 5 mg/mL 10 mL vials on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=527>

### Cefotaxime Injection

**April 11, 2017**

#### Reason for the Shortage

- Hospira has discontinued Claforan. Sanofi-Aventis manufactured Claforan for Hospira and is no longer making the product.
- Baxter discontinued Claforan in late-2015.
- West-Ward has cefotaxime on shortage due to increased demand.

#### Estimated Resupply Dates

- West-Ward has cefotaxime 500 mg, 1 gram, and 2 gram vials on allocation. The 10 gram vials are on long-term back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=826>

### Oxytocin Injection

**April 12, 2017**

#### Reason for the Shortage

- Fresenius Kabi states the shortage was due to increased demand.
- Par Sterile Products (formerly JHP) discontinued generic oxytocin injection in July 2014. Par Sterile Products discontinued Pitocin 10 unit/mL 50 mL vials in September 2015.
- West-Ward is not actively marketing oxytocin.

#### Estimated Resupply Dates

- Fresenius Kabi has oxytocin 10 units/mL 10 mL vials are available with an expiration date of 5 months.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=876>

### Potassium Phosphate Injection

April 13, 2017

#### Reason for the Shortage

- American Regent has not had potassium phosphate injection available since 2012. It is unclear if and when product will return to market.
- Fresenius Kabi has potassium phosphate injection on shortage due to increased demand.
- Pfizer has potassium phosphate injection on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Fresenius Kabi has potassium phosphate 3 mmol/mL 5 mL, 15 mL, and 50 mL vials on back order and the company estimates a release date of early-May 2017 for the 5 mL and 50 mL vials, and early-June 2017 for the 15 mL vials.
- Pfizer has potassium phosphate 3 mmol/mL 15 mL vials on back order and the company estimates a release date of early-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=709>

### Magnesium Sulfate Injection

April 13, 2017

#### Reason for the Shortage

- American Regent has had magnesium sulfate unavailable since late 2012.
- Fresenius Kabi has magnesium sulfate injection on shortage due to increased demand for the product.
- Pfizer has magnesium sulfate injection on shortage due to manufacturing delays.
- X-Gen has magnesium sulfate injection available.

#### Estimated Resupply Dates

- Fresenius Kabi has magnesium sulfate 500 mg/mL 50 mL vials on back order and the company estimates a release date of early-May 2017.
- Pfizer has magnesium sulfate 500 mg/mL 10 mL syringes and 20 mL vials on back order and the company estimates a release date of 3rd quarter 2017 for the 10 mL syringes and 1st quarter 2018 for the 20 mL vials.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=757>

### Lidocaine with Epinephrine Injection

April 13, 2017

#### Reason for the Shortage

- Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
- Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Pfizer has 1% lidocaine with epinephrine (1:100,000) 20 mL and 30 mL vials on back order and the company estimates a release date of early-June 2017 for the 20 mL vials and late-May 2017 for the 30 mL vials. The 1% lidocaine with epinephrine (1:100,000) 50 mL vials are on allocation. The 0.5% lidocaine with epinephrine (1:200,000) 50 mL vials are on back order and the company estimates a release date of September 2017. The 2% lidocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of mid-April 2017. The 2% lidocaine with epinephrine (1:100,000) 30 mL vials are on back order and the company cannot estimate a release date. The 2% lidocaine with

epinephrine (1:100,000) 20 mL vials are on back order and the company estimates a release date of late-May 2017.

- Fresenius Kabi has 0.5% Xylocaine with epinephrine (1:200,000) 50 mL vials on back order and the company estimates a release date of late-April 2017. The 1% Xylocaine with epinephrine (1:200,000) 10 mL and 50 mL vials are back order and the company estimates a release date of early-May 2017 for the 10 mL vials and late-April 2017 for the 50 mL vials. The 1% Xylocaine-MPF with epinephrine (1:200,000) 10 mL and 30 mL vials are on back order and the company estimates a release date of late-April 2017 for the 10 mL vials and mid-April 2017 for the 30 mL vials. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of mid-May 2017. The 2% Xylocaine with epinephrine (1:200,000) 20 mL vials are on back order and the company estimates a release date of late-April 2017. The 2% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company estimates a release date of early- to mid-May 2017. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials in sterile packs are on back order and the company estimates a release date of mid-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=860>

### Clindamycin Injection

**April 13, 2017**

#### Reason for the Shortage

- Akorn did not provide a reason for the shortage.
- Alvogen has clindamycin injection available.
- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer has Cleocin available.
- Sagent has clindamycin injection available.
- Sandoz has clindamycin injection available.

#### Estimated Resupply Dates

- Fresenius Kabi has clindamycin 150 mg/mL 2 mL vials available with short expiration dating of <2 months. The 6 mL vials and 60 mL bulk vials are on back order and the company cannot estimate a release date.
- Sagent has clindamycin 150 mg/mL 60 mL bulk vials available with an expiration date of June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1029>

### Cisplatin Injection

**April 13, 2017**

#### Reason for the Shortage

- Fresenius Kabi has cisplatin available.
- Mylan Institutional could not provide a reason for the shortage.
- Teva has cisplatin available.
- WG Critical Care has cisplatin available.

#### Estimated Resupply Dates

- Fresenius Kabi has cisplatin 50 mL and 100 mL vials on back order and the company estimates a release date of mid-April 2017.
- Mylan Institutional has cisplatin 50 mL and 100 mL vials temporarily unavailable and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=57>

### Calcium Gluconate Injection

April 13, 2017

#### Reason for the Shortage

- American Regent has calcium gluconate on shortage due to manufacturing delays.
- Fresenius Kabi has calcium gluconate available with alternating short-dating due to manufacturing process of the vials.
- American Regent has issued a statement that all lots of calcium gluconate may contain glass particles and filters must be used. Do not use if there are visible glass particles and filter all other product.

#### Estimated Resupply Dates

- American Regent has calcium gluconate 100 mg/mL 50 mL and 100 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has calcium gluconate 100 mg/mL 10 mL and 50 mL vials on back order and the company estimates a release date of early-May 2017. The 100 mL vials are on intermittent back order with regular releases.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=48>

### Bleomycin Sulfate Injection

April 13, 2017

#### Reason for the Shortage

- Fresenius Kabi has bleomycin on back order due to shortage of active pharmaceutical ingredient.
- Pfizer has bleomycin available.
- Teva has bleomycin available.
- FDA is allowing temporary importation of bleomycin sulfate powder for injection 15,000 IU (15 units bleomycin sulfate USP). These vials were manufactured for Amneal Australia. The labeling and bar coding for the imported product is different from the US version. The imported product should be used in the same way as the US product. FDA Dear Healthcare Professional letter. The product should be available to order through major wholesalers.

#### Estimated Resupply Dates

- Fresenius Kabi has bleomycin 15 unit and 30 unit vials on back order and the company estimates a release date of 3rd quarter 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1233>

### Tobramycin Injection

April 14, 2017

#### Reason for the Shortage

- Akorn has tobramycin injection on shortage due to manufacturing delays.
- Mylan Institutional could not provide a reason for the shortage.

#### Estimated Resupply Dates

- Akorn has tobramycin 40 mg/mL 2 mL and 30 mL vials on back order and the company cannot estimate a release date.
- Mylan Institutional has tobramycin 40 mg/mL 2 mL vials on back order and the company estimates a release date of mid-April 2017.
- Fresenius Kabi has tobramycin 1.2 gram preservative-free lyophilized powder for injection 50 mL vials on back order and the company estimates a release date of late-April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=701>

### **Sodium Bicarbonate Injection**

**April 18, 2017**

Reason for the Shortage

- Amphastar has sodium bicarbonate injection on shortage due to manufacturing delays.
- Pfizer has sodium bicarbonate injection on shortage due to manufacturing delays.

Estimated Resupply Dates

- Amphastar has 8.4 % sodium bicarbonate 50 mL syringes available in limited supply.
- Pfizer has 8.4 % sodium bicarbonate 50 mL syringes and 50 mL vials on allocation. The 8.4% sodium bicarbonate 10 mL syringes are on back order and the company estimates a release date of May 2017. The 7.5% sodium bicarbonate 50 mL syringes are on allocation. The 4.2% sodium bicarbonate 10 mL syringes are on back order and the company estimates a release date of early-June 2017.
- Pfizer has Neut additive solution in 5 mL vials on back order and the company estimates a release date of early-May 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=788>

### **Hydroxyzine Hydrochloride Injection**

**April 18, 2017**

Reason for the Shortage

- American Regent would not provide a reason for the shortage. They are the sole supplier of hydroxyzine injection.

Estimated Resupply Dates

- American Regent has hydroxyzine 25 mg/mL 1 mL vials, 50 mg/mL 2mL vials, and 50 mg/mL 10 mL vials on back order and the company cannot estimate a release date. The 50 mg/mL 1 mL vials are available in limited supply with an expiration date of August 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1185>

### **Erythromycin Lactobionate Injection**

**April 18, 2017**

Reason for the Shortage

- Pfizer (Hospira) has Erythrocin on shortage due to manufacturing delays.

Estimated Resupply Dates

- Pfizer (Hospira) has Erythrocin 500 mg ADD-Vantage vials on back order and the company estimates a release date of April 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=546>

### **Dobutamine Injection**

**April 18, 2017**

Reason for the Shortage

- Baxter did not provide a reason for the shortage.

- Pfizer has dobutamine on shortage due to manufacturing delays.

#### Estimated Resupply Dates

- Baxter has dobutamine 2 mg/mL 250 mL bags available in limited supply.
- Pfizer has dobutamine 12.5 mg/mL 20 mL and 40 mL latex-free vials on back order with an estimated release date of 2018.
- Pfizer has dobutamine 2 mg/mL 250 mL bags on intermittent back order and the company is releasing product as it becomes available. The dobutamine 1 mg/mL 250 mL bags are on back order and the company cannot estimate a release date.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=929>

### Calcium Chloride Injection

**April 18, 2017**

#### Reason for the Shortage

- American Regent has calcium chloride on shortage due to manufacturing delays.
- Amphastar has calcium chloride on shortage due to increased demand.
- Pfizer has calcium chloride on shortage due to manufacturing delays.
- Mylan Institutional has withdrawn calcium chloride syringes from the market. The company recalled the syringes in April 2015 due to incompatibility of the syringes and some needless adaptors.

#### Estimated Resupply Dates

- American Regent has calcium chloride 100 mg/mL 10 mL vials on back order and the company cannot estimate a release date.
- Amphastar has calcium chloride 100 mg/mL 10 mL syringes on intermittent back order with regular releases.
- Pfizer has calcium chloride 100 mg/mL 10 mL Ansy syringes on back order and the company estimates a release date of early-May 2017. The 100 mg/mL 10 mL LifeShield syringes are on back order and the company estimates a release date of late-June 2017.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=941>

### 70% Dextrose Injection Large Volume Bags

**April 18, 2017**

#### Reason for the Shortage

- Baxter has 70% dextrose 2,000 mL bags on shortage due to manufacturing delays.
- BBraun discontinued 70% dextrose in 1,000 mL glass bottles in 2016. The 70% dextrose 2,000 mL bags are on allocation due to increased demand.
- Pfizer had 70% dextrose 500 mL in 1000 mL partial fill bags on back order due to manufacturing delays.

#### Estimated Resupply Dates

- Baxter has 70% dextrose 2,000 mL bags on intermittent back order with regular releases.
- BBraun has 70% dextrose 2,000 mL bags on allocation to current customers.

<https://www.ashp.org/Drug-Shortages/Current-Shortages/Drug-Shortage-Detail.aspx?id=1133>